WO2024022165A1 - 依沙替康衍生物及其应用 - Google Patents
依沙替康衍生物及其应用 Download PDFInfo
- Publication number
- WO2024022165A1 WO2024022165A1 PCT/CN2023/107930 CN2023107930W WO2024022165A1 WO 2024022165 A1 WO2024022165 A1 WO 2024022165A1 CN 2023107930 W CN2023107930 W CN 2023107930W WO 2024022165 A1 WO2024022165 A1 WO 2024022165A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- alkyl
- gly
- add
- Prior art date
Links
- ZVYVPGLRVWUPMP-FYSMJZIKSA-N exatecan Chemical class C1C[C@H](N)C2=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC3=CC(F)=C(C)C1=C32 ZVYVPGLRVWUPMP-FYSMJZIKSA-N 0.000 title abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 34
- 229940002612 prodrug Drugs 0.000 claims abstract description 17
- 239000000651 prodrug Substances 0.000 claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims description 133
- -1 amino, methyl Chemical group 0.000 claims description 86
- 238000006243 chemical reaction Methods 0.000 claims description 70
- 239000000611 antibody drug conjugate Substances 0.000 claims description 21
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 21
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 19
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 239000001257 hydrogen Substances 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 15
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 10
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 7
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 201000004101 esophageal cancer Diseases 0.000 claims description 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 150000001408 amides Chemical class 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 108090000629 orphan nuclear receptors Proteins 0.000 claims description 6
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical group CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 claims description 5
- HXUVTXPOZRFMOY-NSHDSACASA-N 2-[[(2s)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-phenylpropanoyl]amino]acetic acid Chemical group NCC(=O)NCC(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 HXUVTXPOZRFMOY-NSHDSACASA-N 0.000 claims description 5
- 239000000427 antigen Substances 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 229940127121 immunoconjugate Drugs 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 150000002429 hydrazines Chemical class 0.000 claims description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 claims description 4
- AAQGRPOPTAUUBM-ZLUOBGJFSA-N Ala-Ala-Asn Chemical group [H]N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O AAQGRPOPTAUUBM-ZLUOBGJFSA-N 0.000 claims description 3
- 101150029707 ERBB2 gene Proteins 0.000 claims description 3
- QITBQGJOXQYMOA-ZETCQYMHSA-N Gly-Gly-Lys Chemical group NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CN QITBQGJOXQYMOA-ZETCQYMHSA-N 0.000 claims description 3
- IKAIKUBBJHFNBZ-LURJTMIESA-N Gly-Lys Chemical group NCCCC[C@@H](C(O)=O)NC(=O)CN IKAIKUBBJHFNBZ-LURJTMIESA-N 0.000 claims description 3
- YIKSCQDJHCMVMK-UHFFFAOYSA-N Oxamide Chemical compound NC(=O)C(N)=O YIKSCQDJHCMVMK-UHFFFAOYSA-N 0.000 claims description 3
- HSRXSKHRSXRCFC-WDSKDSINSA-N Val-Ala Chemical group CC(C)[C@H](N)C(=O)N[C@@H](C)C(O)=O HSRXSKHRSXRCFC-WDSKDSINSA-N 0.000 claims description 3
- 238000009833 condensation Methods 0.000 claims description 3
- 230000005494 condensation Effects 0.000 claims description 3
- 239000000562 conjugate Substances 0.000 claims description 3
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 3
- 108010015792 glycyllysine Chemical group 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 2
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 2
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 abstract description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 84
- 239000000243 solution Substances 0.000 description 68
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 55
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 54
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 44
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 43
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 41
- 238000003756 stirring Methods 0.000 description 38
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 31
- 239000012071 phase Substances 0.000 description 29
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 23
- 239000007787 solid Substances 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 238000010898 silica gel chromatography Methods 0.000 description 18
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- 230000002401 inhibitory effect Effects 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 13
- 238000004587 chromatography analysis Methods 0.000 description 13
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 13
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- HYSPJPGXSALJRR-DHIFEGFHSA-N [4-[[(2s)-5-(carbamoylamino)-2-[[(2s)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl (4-nitrophenyl) carbonate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=O)C(=O)NC=1C=CC(COC(=O)OC=2C=CC(=CC=2)[N+]([O-])=O)=CC=1)C(=O)CCCCCN1C(=O)C=CC1=O HYSPJPGXSALJRR-DHIFEGFHSA-N 0.000 description 12
- 125000000217 alkyl group Chemical group 0.000 description 12
- 235000008504 concentrate Nutrition 0.000 description 11
- 239000012141 concentrate Substances 0.000 description 11
- 235000019439 ethyl acetate Nutrition 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 239000007821 HATU Substances 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 150000002923 oximes Chemical class 0.000 description 8
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000012265 solid product Substances 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- MMGQHUVSVCDSBI-UHFFFAOYSA-N 2-hydrazinyl-n-methyl-2-oxoacetamide Chemical compound CNC(=O)C(=O)NN MMGQHUVSVCDSBI-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- PBVAJRFEEOIAGW-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)phosphanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCP(CCC(O)=O)CCC(O)=O PBVAJRFEEOIAGW-UHFFFAOYSA-N 0.000 description 5
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 5
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 5
- 101001024703 Homo sapiens Nck-associated protein 5 Proteins 0.000 description 5
- 102100036946 Nck-associated protein 5 Human genes 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 5
- 239000008351 acetate buffer Substances 0.000 description 5
- HABAJMUFCIDFOT-JEDNCBNOSA-N acetic acid;(2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid Chemical compound CC(O)=O.OC(=O)[C@@H](N)CC1=CN=CN1 HABAJMUFCIDFOT-JEDNCBNOSA-N 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 150000007942 carboxylates Chemical class 0.000 description 5
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 5
- 239000012065 filter cake Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 229940068977 polysorbate 20 Drugs 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 125000006413 ring segment Chemical group 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 150000008065 acid anhydrides Chemical class 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 150000001340 alkali metals Chemical class 0.000 description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 229940126543 compound 14 Drugs 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 125000005366 cycloalkylthio group Chemical group 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- UZRUVUYVHGPEAP-UHFFFAOYSA-N tert-butyl n-(methylamino)carbamate Chemical compound CNNC(=O)OC(C)(C)C UZRUVUYVHGPEAP-UHFFFAOYSA-N 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 2
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 2
- TZGPACAKMCUCKX-UHFFFAOYSA-N 2-hydroxyacetamide Chemical class NC(=O)CO TZGPACAKMCUCKX-UHFFFAOYSA-N 0.000 description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 2
- 125000005916 2-methylpentyl group Chemical group 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000005917 3-methylpentyl group Chemical group 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 150000001241 acetals Chemical class 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- 201000008274 breast adenocarcinoma Diseases 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 150000002373 hemiacetals Chemical class 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 229940071870 hydroiodic acid Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- LLAZQXZGAVBLRX-UHFFFAOYSA-N methyl 2,5-dioxopyrrole-1-carboxylate Chemical compound COC(=O)N1C(=O)C=CC1=O LLAZQXZGAVBLRX-UHFFFAOYSA-N 0.000 description 2
- ZXUQEPZWVQIOJE-UHFFFAOYSA-N methyl 2-chloro-2-oxoacetate Chemical compound COC(=O)C(Cl)=O ZXUQEPZWVQIOJE-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 229960002087 pertuzumab Drugs 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 2
- 150000003871 sulfonates Chemical class 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- NXQXVXILNVTMNA-UHFFFAOYSA-N tert-butyl n-(6-bromohexyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCCCCBr NXQXVXILNVTMNA-UHFFFAOYSA-N 0.000 description 2
- DMOPZPBTLCZSGL-UHFFFAOYSA-N tert-butyl n-[2-(2-bromoethoxy)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCOCCBr DMOPZPBTLCZSGL-UHFFFAOYSA-N 0.000 description 2
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 2
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 229940049679 trastuzumab deruxtecan Drugs 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- UFGUUZVZUIXKQZ-DEOSSOPVSA-N (2S)-2-[[2-[[2-(9H-fluoren-9-ylmethoxycarbonylamino)acetyl]amino]acetyl]amino]-3-phenylpropanoic acid Chemical compound C1=CC=CC=2C3=CC=CC=C3C(C1=2)COC(=O)NCC(=O)NCC(=O)N[C@H](C(=O)O)CC1=CC=CC=C1 UFGUUZVZUIXKQZ-DEOSSOPVSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- VTWKXBJHBHYJBI-VURMDHGXSA-N (nz)-n-benzylidenehydroxylamine Chemical compound O\N=C/C1=CC=CC=C1 VTWKXBJHBHYJBI-VURMDHGXSA-N 0.000 description 1
- WLDRFJDGKMTPPV-UHFFFAOYSA-N 1,2-dimethylhydrazine dihydrochloride Chemical compound Cl.Cl.CNNC WLDRFJDGKMTPPV-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- GIAFURWZWWWBQT-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanol Chemical compound NCCOCCO GIAFURWZWWWBQT-UHFFFAOYSA-N 0.000 description 1
- QBXODCKYUZNZCY-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]oxyacetic acid Chemical compound CC(C)(C)OC(=O)NOCC(O)=O QBXODCKYUZNZCY-UHFFFAOYSA-N 0.000 description 1
- FBKUOPULLUJMOC-UHFFFAOYSA-N 2-[[2-(9h-fluoren-9-ylmethoxycarbonylamino)acetyl]amino]acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 FBKUOPULLUJMOC-UHFFFAOYSA-N 0.000 description 1
- OVHAGSAFAIGAGZ-UHFFFAOYSA-N 2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]oxyacetic acid Chemical compound OC(=O)CON(C)C(=O)OC(C)(C)C OVHAGSAFAIGAGZ-UHFFFAOYSA-N 0.000 description 1
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
- XIMFTYYMYOBGOG-UHFFFAOYSA-N 2-hydroxy-2-(2-oxo-2-propoxyethyl)butanedioic acid Chemical compound CCCOC(=O)CC(O)(C(O)=O)CC(O)=O XIMFTYYMYOBGOG-UHFFFAOYSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004336 3,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- IIINBAWOESLQTR-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]oxetane-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)NC1(C(O)=O)COC1 IIINBAWOESLQTR-UHFFFAOYSA-N 0.000 description 1
- LXRNYRAHXDUNKR-UHFFFAOYSA-N 3-azaniumyloxetane-3-carboxylate Chemical compound OC(=O)C1(N)COC1 LXRNYRAHXDUNKR-UHFFFAOYSA-N 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- SUTWPJHCRAITLU-UHFFFAOYSA-N 6-aminohexan-1-ol Chemical compound NCCCCCCO SUTWPJHCRAITLU-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 102100039614 Nuclear receptor ROR-alpha Human genes 0.000 description 1
- 101100272976 Panax ginseng CYP716A53v2 gene Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229910020008 S(O) Chemical group 0.000 description 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- MKRNVBXERAPZOP-UHFFFAOYSA-N Starch acetate Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OC(C)=O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 MKRNVBXERAPZOP-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 101150041570 TOP1 gene Proteins 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 229950009429 exatecan Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- RGZRSLKIOCHTSI-UHFFFAOYSA-N hydron;n-methylhydroxylamine;chloride Chemical compound Cl.CNO RGZRSLKIOCHTSI-UHFFFAOYSA-N 0.000 description 1
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- ACKFDYCQCBEDNU-UHFFFAOYSA-J lead(2+);tetraacetate Chemical compound [Pb+2].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ACKFDYCQCBEDNU-UHFFFAOYSA-J 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- VJFVFPGICMXFCT-UHFFFAOYSA-N n-ethoxyhydroxylamine;hydrochloride Chemical compound Cl.CCONO VJFVFPGICMXFCT-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- HVZWVEKIQMJYIK-UHFFFAOYSA-N nitryl chloride Chemical compound [O-][N+](Cl)=O HVZWVEKIQMJYIK-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000004816 paper chromatography Methods 0.000 description 1
- 239000005426 pharmaceutical component Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- DKACXUFSLUYRFU-UHFFFAOYSA-N tert-butyl n-aminocarbamate Chemical compound CC(C)(C)OC(=O)NN DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 1
- BFTVWTYYQWTLQL-UHFFFAOYSA-N tert-butyl n-hydroxy-n-methylcarbamate Chemical compound CN(O)C(=O)OC(C)(C)C BFTVWTYYQWTLQL-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Definitions
- the present invention relates to the field of biomedicine, specifically to ixatecan derivatives and their applications.
- Exatecan is a fully synthetic derivative of the natural product camptothecin. It has strong inhibitory activity against topoisomerase Top1, can promote tumor cell apoptosis, and has broad-spectrum anti-tumor activity. Ixanotecan has limited its application in the field of anti-tumor drugs due to its severe side effects. Its hydroxyacetamide derivative (Dxd) is used as a toxin and trastuzumab (Herceptin) is an antibody-conjugated drug DS- 8201a (antibody-drugconjugate, ADC) has a very good therapeutic effect on Her2-expressing tumors. DS-8201a is an ADC anti-tumor drug with excellent performance. In addition to Herceptin, ADC drugs targeting other antigens such as B7-H3, Trop2, etc. are also being widely studied.
- ADC drugs targeting other antigens such as B7-H3, Trop2, etc. are also being widely studied.
- the present invention derivatizes ixanotecan with hydroxylamine and hydrazine to form a series of ixanotecan derivatives with coupling sites. These compounds have high anti-tumor activity. , low toxicity and side effects, and easily soluble in water, it has potential application value as an anti-tumor single drug or antibody-conjugated drug.
- the invention provides a series of structurally novel isatecan derivatives, their pharmaceutically acceptable salts, stereoisomers or prodrugs, and their applications in the field of anti-tumor.
- One aspect of the invention provides a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof:
- R 1 is selected from -(CH 2 ) n NR a R b , -CH 2 OR a , -NOR a , -(CH 2 ) n ONR a R b or -R 3 ; n is selected from 0, 1, 2 or 3 ;
- R a and R b are each independently selected from hydrogen, hydroxyl, amino, C 1 -C 6 alkyl, C 1 -C 6 alkylamino, amino C 1 -C 6 alkyl or C 1 -C 6 alkoxy;
- R 3 is selected from 3 to 6-membered cycloalkyl or 3 to 6-membered heterocycloalkyl containing N, O, or S heteroatoms, R 3 is optionally further substituted by R c ;
- R c is selected from hydrogen, hydroxyl, amino, C 1 -C 6 alkyl, C 1 -C 6 alkylamino or C 1 -C 6 alkoxy;
- -ZR 1 is not -NH 2 , -CH 2 OH, -CH 2 NH 2 or -CH 2 OCH 2 NH 2 .
- R 1 is not -CH 2 ONH 2 or hydroxyoxetanyl.
- R 1 is selected from -NR a R b , -CH 2 NR a R b , -CH 2 OR a , -NORa , -(CH 2 ) n ONR a R b or -R 3 .
- R 1 is selected from -NR a R b , -C(O)NR a R b , -CH 2 NR a R b , -CH 2 ONR a R b or -R 3 .
- R a and R b are each independently selected from hydrogen, hydroxyl, amino, C 1 -C 6 alkyl, C 1 -C 6 alkylamino or C 1 -C 6 alkoxy.
- R a and R b are each independently selected from hydrogen, hydroxyl, amino, methyl, methylamino or methoxy.
- R 3 is selected from 3 to 6-membered heterocycloalkyl containing N, O, or S heteroatoms, and R 3 is optionally further substituted by R c ; said R c is selected from hydrogen, hydroxyl , amino, C 1 -C 6 alkyl, C 1 -C 6 alkylamino or C 1 -C 6 alkoxy.
- R 1 is selected from -NHNH 2 , -N(CH 3 )NH 2 , -N(CH 3 )NHCH 3 , -C(O)NHNH 2 , -C(O)N(CH 3 ) NH 2 , -CH 2 NHOH , -CH 2 NHOCH 3 , -CH 2 ONH 2 , -CH 2 ONHCH 3 , -CH 2 NCH 3 NH 2 , -CH 2 N(CH 3 )NHCH 3 , -CH 2 N( CH 3 )OH, -CH 2 NHOCH 2 CH 3 , hydroxyoxetanyl Aminooxetanyl
- R 1 is selected from -NHNH 2 , -N(CH 3 )NH 2 , -N(CH 3 )NHCH 3 , -C(O)NHNH 2 , -C(O)N(CH 3 ) NH 2 ,- CH 2 NHOH, -CH 2 NHOCH 3 , -CH 2 ONHCH 3 , -CH 2 NCH 3 NH 2 , -CH 2 N(CH 3 )NHCH 3 , -CH 2 N(CH 3 )OH, -CH 2 NHOCH 2 CH 3 , aminooxetanyl
- the compound of formula (I) is a compound of formula (Ia):
- R 1 is defined the same as the compound of formula (I).
- R 1 is -NHNH 2 or -N(CH 3 )NH 2 .
- the compound of formula (I) is a compound of formula (Ib):
- R 2 is selected from -NHOH, -ONH 2 , -NHO (C 1 -C 3 alkyl), -ONH (C 1 -C 3 alkyl), -N (C 1 -C 3 alkylamino), -N(C 1 -C 3 alkyl)NH(C 1 -C 3 alkyl), -N(C 1 -C 3 alkyl)OH or -NHO(C 1 -C 3 alkyl).
- R 2 is selected from -NHOH, -NHOCH 3 , ONH 2 , -ONHCH 3 , -NCH 3 NH 2 , -N(CH 3 )NHCH 3 , -N(CH 3 )OH or -NHOCH 2 CH 3 .
- R 2 is selected from -NHOH, -NHO(C 1 -C 3 alkyl), -ONH(C 1 -C 3 alkyl), -N(C 1 -C 3 alkylamino), - N(C 1 -C 3 alkyl)NH(C 1 -C 3 alkyl), -N(C 1 -C 3 alkyl)OH or -NHO(C 1 -C 3 alkyl).
- R 2 is selected from -NHOH, -NHOCH 3 , -ONHCH 3 , -NCH 3 NH 2 , -N(CH 3 )NHCH 3 , -N(CH 3 )OH or -NHOCH 2 CH 3 .
- the compound of formula (I) is a compound of formula (Ic):
- R a and R b are defined the same as the compound of formula (I); the condition is that R a and R b are not H at the same time.
- R a and R b are each independently selected from hydrogen, amino, C 1 -C 3 alkyl, C 1 -C 3 alkylamino.
- -NR a R b is selected from -NHNH 2 , -N(CH 3 )NH 2 or -N(CH 3 )NHCH 3 .
- the compound of formula (I) is a compound of formula (Id):
- X is CH 2 , NH, O or S.
- X is CH2 or O; more preferably, X is O.
- R c is selected from hydrogen, hydroxy, amino, C 1 -C 6 alkyl, C 1 -C 6 alkylamino, or C 1 -C 6 alkoxy.
- R c is selected from hydroxyl or amino, more preferably amino.
- the compound of formula (I) is selected from the following compounds:
- Another aspect of the present invention provides a method for preparing the compound described in any one of the above, which is selected from the following reaction routes:
- Ixanotecan is reacted with N,N'-carbonyldiimidazole, and then reacted with hydrazine or substituted hydrazine to obtain the corresponding N-semicarbazide isotecan derivative.
- the substituted hydrazine is reacted with oxalyl chloride, and then reacted with isatecan to obtain the corresponding oxalamide hydrazine-ixatecan derivative.
- Ixanotecan reacts directly with carboxylic acid compounds to obtain the corresponding amide idecan derivatives.
- R and L are defined the same as the compound of formula (I).
- R is defined as the compound of formula (I).
- L is -L 1 -QL 2 ; R is attached to the L 1 moiety.
- L 1 is selected from in, The position shown indicates attachment to the R group, The position shown indicates attachment to the Q group.
- L2 is selected from
- Q is selected from Val-Cit, Val-Ala, Ala-Ala-Asn, Gly-Gly-Phe-Gly, Gly-Lys, Gly-Gly-lys, (CH 2 ) m1 O(CH 2 ) m2 , (CH 2 ) m3 , wherein m1 and m2 are each independently selected from an integer of 1-4.
- m1 is 2.
- m2 is 2.
- m3 is 6.
- Q is selected from Val-Cit, Gly-Gly-Phe-Gly, (CH 2 ) 2 O(CH 2 ) 2 , or (CH 2 ) 6 ;
- L 1 is N
- L 2 is
- the present invention provides a drug-antibody coupling compound represented by formula (III) or a pharmaceutically acceptable salt thereof:
- R has the same definition as formula (I) or compound
- L has the same definition as formula (II) or compound.
- Ab is a tumor-associated antigen antibody, and n is selected from an integer of 1-8.
- the tumor-associated antigen is selected from Her2, Trop2, 5T4, ROR1 or B7-H3.
- the Ab is Pertuzumab.
- the drug-antibody conjugate compound of formula (III) is selected from the following compounds:
- the drug-antibody conjugate compound of formula (II) is selected from the following compounds:
- a pharmaceutical composition which includes the above compound, a drug-linker compound or a pharmaceutically acceptable salt, stereoisomer, prodrug or antibody drug conjugate thereof.
- the pharmaceutical composition further includes pharmaceutically acceptable excipients.
- the cancer includes gastric cancer, esophageal cancer, breast cancer and lung adenocarcinoma.
- Another aspect of the present invention provides a method of treating cancer, comprising administering the above compound or a pharmaceutically acceptable salt, stereoisomer, prodrug, antibody drug conjugate or drug combination thereof to a patient in need thereof object steps.
- the administered amount of the above compound or its pharmaceutically acceptable salt, stereoisomer, prodrug, antibody drug conjugate or pharmaceutical composition is a therapeutically effective amount.
- the compounds of the present invention may be asymmetric, eg, have one or more stereoisomers. Unless otherwise stated, all stereoisomers include, for example, enantiomers and diastereomers.
- the stereoisomers include geometric isomers (such as cis and trans structures) and optical isomers (such as enantiomers), in the form of monomers, racemates, racemic mixtures and pharmaceutically acceptable The treatment consisting of salt received.
- the compounds of the present invention containing asymmetric carbon atoms can be isolated in optically active pure form or in racemic form. Optically active pure forms can be resolved from racemic mixtures or synthesized by using chiral starting materials or chiral reagents. Racemates, diastereomers, and enantiomers are all included within the scope of the present invention.
- the compounds of the present invention also include tautomeric forms.
- the tautomeric form results from the exchange of a single bond with an adjacent double bond and the accompanying migration of a proton.
- salts refer to salts of the corresponding amine compounds with inorganic or organic acids, or salts of the corresponding carboxylic acid compounds with alkali metals or alkaline earth metals, or with organic amines. of salt.
- inorganic acids include but are not limited to hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, etc.
- organic acids include but are not limited to acetic acid, propionic acid, butyric acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, and p-toluene.
- precursor means that after the compound enters the human body in an appropriate manner of administration, the precursor compound undergoes metabolism or simple chemical changes in the patient's body and is converted into the compound contained in the general formula 1 of the present invention and the corresponding salt. form.
- Precursors of compounds include but are not limited to various carboxylates, carbonates, phosphates, sulfates, sulfonates, amino acid esters, gluconates, and various amides, acetals, hemiacetals, carbonate amide esters, etc. .
- C1-C6 means that the group can have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms;
- C3-C6 is means that the group can have 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms.
- any variable e.g., Rn
- Rn variable
- its definition in each instance is independent.
- R for example, if a group is substituted by 1 to 5 R, then said group may optionally be substituted with up to 5 R, with independent options for R in each case.
- substituents and/or variants thereof are permitted only if such combinations result in stable compounds.
- alkyl refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 8 carbon atoms, more preferably 1 to 6 carbon atoms an alkyl group, most preferably an alkyl group having 1 to 3 carbon atoms.
- Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1 , 2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2- Methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3 -Dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2 -Methylhexyl, 3-methylhexyl, 4-methylhe
- lower alkyl groups containing 1 to 6 carbon atoms include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl base, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-Methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethyl Butyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl base, 2,3-dimethylbutyl, etc.
- Alkyl groups may be substituted or unsubstituted. When substituted, the substituents may be substituted at any available point of attachment.
- the substituents are preferably one or more of the following groups, independently selected from alkyl groups: Base, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyl Oxygen group, heterocycloalkyloxy group, cycloalkylthio group, heterocycloalkylthio group, oxo group, carboxyl group or carboxylate group.
- methyl group, ethyl group, isopropyl group, tert-butyl group and haloalkyl group are preferred.
- heterocyclyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent containing 3 to 20 ring atoms, one or more of which are selected from nitrogen, oxygen, or S(O) heteroatoms of m (where m is an integer from 0 to 2), but excluding the ring portion of -OO-, -OS- or -SS-, the remaining ring atoms for carbon.
- the one-membered heterocyclyl group is optionally substituted by 1-2 oxygen atoms, sulfur atoms, and oxo groups, including nitrogen-containing monocyclic heterocyclyl groups, nitrogen-containing spiroheterocyclyl groups, or nitrogen-containing fused heterocyclyl groups.
- aryl refers to a 6 to 14 membered all-carbon monocyclic or fused polycyclic (i.e., rings sharing adjacent pairs of carbon atoms) group having a conjugated pi electron system, preferably 6 to 12 members, such as benzene base and naphthyl.
- the aryl group may be substituted or unsubstituted.
- the substituent is preferably one or more of the following groups, which are independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, Alkylamino, halogen, mercapto, hydrogen, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, Heterocycloalkylthio group, carboxyl group or carboxylate group.
- alkoxy refers to -O-(alkyl) and -O-(unsubstituted cycloalkyl), where alkyl is as defined above.
- alkoxy include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy.
- the alkoxy group may be optionally substituted or unsubstituted.
- the substituent is preferably one or more of the following groups, which are independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkyl, Thio, alkylamino, halogen, mercapto, hydrogen, nitro, chlorine, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkyl Thio group, heterocycloalkylthio group, carboxyl group or carboxylate group.
- groups which are independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkyl, Thio, alkylamino, halogen, mercapto, hydrogen, nitro, chlorine, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkyl Thio group, heterocycloalkylthio group
- the hydrogen atoms described in the present invention can be replaced by its isotope deuterium.
- Substituted means that one or more hydrogen atoms in a group, preferably up to 5, more preferably 1 to 3 hydrogen atoms, are independently substituted with a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and the person skilled in the art is able to determine (either experimentally or theoretically) possible or impossible substitutions without undue effort. For example, an amino or hydroxyl group with a free hydrogen may be unstable when combined with a carbon atom with an unsaturated (eg, olefinic) bond.
- salts refer to salts of the corresponding amine compounds with inorganic or organic acids, or salts of the corresponding carboxylic acid compounds with alkali metals or alkaline earth metals, or with organic amines. of salt.
- inorganic acids include but are not limited to hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, etc.
- organic acids include but are not limited to acetic acid, propionic acid, butyric acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, and p-toluene.
- precursor means that after the compound enters the human body in an appropriate manner of administration, the precursor compound undergoes metabolism or simple chemical changes in the patient's body and is converted into the compound contained in the general formula 1 of the present invention and the corresponding salt. form.
- Precursors of compounds include but are not limited to various carboxylates, carbonates, phosphates, sulfates, sulfonates, amino acid esters, gluconates, and various amides, acetals, hemiacetals, carbonate amide esters, etc. .
- the medicaments or pharmaceutical compositions of the invention may be administered orally, topically, parenterally or mucosally (eg, bucally, by inhalation or rectally) in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers Apply. It is usually desirable to use the oral route.
- the active agent may be administered orally in the form of capsules, tablets, etc. (see Remington: The Science and Practice of Pharmacy, 20th Edition).
- the active pharmaceutical ingredient may be combined with non-toxic, pharmaceutically acceptable excipients such as binders (e.g., pregelatinized cornstarch, polyvinylpyrrolidone, or hydroxypropylmethyl).
- binders e.g., pregelatinized cornstarch, polyvinylpyrrolidone, or hydroxypropylmethyl.
- cellulose cellulose
- fillers for example, lactose, sucrose, glucose, mannitol, sorbitol and other reducing and non-reducing sugars, microcrystalline cellulose, calcium sulfate or calcium hydrogen phosphate
- lubricants for example, , magnesium stearate, talc or silica, stearic acid, sodium stearyl fumarate, glyceryl behenate, calcium stearate, etc.
- disintegrating agent for example, potato starch or hydroxyl sodium starch acetate
- wetting agents for example, sodium lauryl sulfate
- coloring and flavoring agents gelatin, sweeteners, natural and synthetic gums (such as acacia, tragacanth or alginate), Buffer salt, carboxymethyl cellulose, polyethylene glycol, wax, etc.
- the pharmaceutical component may be derivatized with a non-toxic, pharmaceutically acceptable inert carrier (e.g., ethanol, glycerol, water), anti-sedimentation agent (e.g., sorbitol syrup, cellulose or hydrogenated edible fats), emulsifiers (e.g., lecithin or gum arabic), non-aqueous carriers (e.g., almond oil, oil esters, ethanol or fractionated vegetable oils), preservatives (e.g., p- Methyl hydroxybenzoate or p-propyl hydroxybenzoate or sorbic acid) and other combinations.
- Stabilizers such as antioxidants (BHA, BHT, propyl citrate, sodium ascorbate, citric acid) may also be added to stabilize the dosage form.
- compositions of the invention which comprise a compound of formula I as active compound may also incorporate beads, microspheres or microcapsules, constructed for example from polyglycolic/lactic acid (PGLA).
- PGLA polyglycolic/lactic acid
- Liquid preparations for oral administration may take the form of, for example, solutions, syrups, emulsions or suspensions or they may be presented as a dry product for constitution with water or other suitable excipients before use.
- Formulations for oral administration may be suitably formulated to provide controlled or delayed release of the active compound.
- treating includes inhibiting, alleviating, preventing, or eliminating one or more symptoms or side effects associated with the disease, condition, or disorder being treated.
- inhibitor is used with respect to control.
- One skilled in the art will readily determine the appropriate controls for each experiment. For example, a reduced response in a subject or cell treated with a compound is compared to a response in a subject or cell not treated with the compound.
- composition means a composition comprising a compound of the present invention or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable ingredient selected from the following, depending on the mode of administration and the nature of the dosage form, Including but not limited to: carriers, diluents, adjuvants, excipients, preservatives, fillers, disintegrants, wetting agents, emulsifiers, suspending agents, sweeteners, flavoring agents, flavors, antibacterial agents , antifungal agents, lubricants, dispersants, temperature-sensitive materials, temperature regulators, adhesives, stabilizers, suspending agents, etc.
- an effective amount refers to a nontoxic amount of a drug or agent that is sufficient to achieve the desired effect.
- the amount of a given drug depends on many factors, such as the specific dosage regimen, the type of disease or condition and its severity, and the subject requiring treatment. or host's uniqueness (e.g., body weight), however, dosages administered may be determined by those known in the art, depending on the particular surrounding circumstances, including, for example, the specific drug being employed, the route of administration, the condition being treated, and the subject or host being treated. The method is routinely determined.
- the dosage administered will typically be in the range of 0.02-5000 mg/day, for example about 1-1500 mg/day.
- the required dose may conveniently be presented as one dose, or as divided doses administered simultaneously (or within a short period of time) or at appropriate intervals, for example two, three, four or more divided doses per day.
- the specific effective amount can be appropriately adjusted according to the patient's condition and in conjunction with the physician's diagnosis.
- ADC antibody-drug conjugate
- the raw materials and equipment used in the specific embodiments of the present invention are all known products and can be obtained by purchasing commercially available products.
- CDI N, N'-carbonyldiimidazole
- EA ethyl acetate
- DCM dichloromethane
- HATU 2-(7-azabenzotriazole)-N,N,N',N'-tetrazole Methylurea hexafluorophosphate
- DIPEA N,N-diisopropylethylamine
- NMP N-methylpyrrolidone
- HOBt 1-hydroxybenzotriazole
- Val valine, its structural formula is Cit: Citrulline, its structural formula is Gly: Glycine, its structural formula is Phe: phenylalanine, its structural formula is Fmoc: Threonine phosphate benzyl ester, its structural formula is Val-Cit: Gly-Gly-Phe-Gly:
- Val-Ala, Ala-Ala-Asn, Gly-Lys, Gly-Gly-lys and other connecting chains can be connected by amino acid condensation methods known in the art.
- the ADC is prepared using, but not limited to, PERTUZUMAB, whose heavy chain amino acid sequence is as follows (SEQ ID NO: 1):
- the light chain amino acid sequence is as follows (SEQ ID NO:2):
- hydroxylamine hydrochloride 113 mg, 1.63 mmol
- TEA 164 mg, 1.62 mmol
- compound 6-a 90 mg, 0.16 mmol
- compound 1 In 0.3 ml of NMP, compound 1 (13.38 mg, 0.027 mmol), DIPEA (10.51 mg, 0.081 mmol), mc-Val-Cit-pab-PNP (20 mg, 0.027 mmol), HOBt (3.66 mg, 0.027 mmol), react at room temperature for 1 hour, inject the reaction solution into a 25g C18 pre-column (first balanced with acetonitrile, then balanced with water, the water phase contains 0.1% TFA), and then passed through medium-pressure reversed-phase C18 chromatography (gradient: 10% to 55 % acetonitrile in water, time 40 min), eluted, and lyophilized to obtain compound DC-3, that is, mc-Val-Cit-pab-formyl-isatecan-N-semicarbazide (13 mg, 45%) as a yellow solid; LCMS :(M+1)+1093.03 (calculated value: 1092.15).
- Example 17 mc-Val-Cit-pab-formyl-ixatecan-N-methyl-N-semicarbazide (DC-4)
- compound 8 In 0.7ml of NMP, compound 8 (33.05mg, 0.063mmol), DIPEA (24.53mg, 0.189mmol), mc-Val-Cit-pab-PNP (70mg, 0.095mmol), HOBt (8.55mg, 0.063 mmol), react at room temperature for 1 hour, inject the reaction solution into a 25g C18 pre-column (first balanced with acetonitrile, then balanced with water, the water phase contains 0.1% TFA), and then passed through medium-pressure reversed-phase C18 chromatography (gradient: 10% to 55 % acetonitrile in water, time 40 min), eluted, and lyophilized to obtain compound DC-7, that is, mc-Val-Cit-pab-formyl-2-methylaminooxyacetyl isatecan (42 mg, 39%) as a yellow solid ; LCMS: (M+1) + 1122.05 (calculated: 1121.09
- Oxygen hexacyclic solution stir the reaction for 3 hours at room temperature, use saturated sodium bicarbonate solution to adjust the pH of the reaction solution to 9 under ice bath conditions, add N-methoxycarbonylmaleimide (700.90mg 4.52mmol ), stir the reaction for 2 hours under ice bath conditions, filter the solid, wash the filter cake with 10 ml of purified water, and dry the filter cake at 35 degrees to obtain the off-white solid product L-20 (1.0g, yield 73.5%) ; LCMS: (M+1) + 302.23 (calculated: 301.34).
- Dissolve DC-3 (0.9 mg, 0.8 mmol) in 0.09 ml of DMA, add it to the above solution system, mix well, and react with a rotating turntable at room temperature for 2 hours. After the reaction is completed, use a NAP-5 gel column (Cytiva) to remove the buffer. The solution was replaced with 20mM L-histidine acetate buffer, pH 6.0, 120mM sucrose, 0.2g/L polysorbate 20, to obtain ADC-3a (1.8mg/ml, 3ml).
- Dissolve DC-6 (0.9 mg, 0.8 mmol) in 0.09 ml of DMA, add it to the above solution system, mix well, and react with a rotating turntable at room temperature for 2 hours. After the reaction is completed, use a NAP-5 gel column (Cytiva) to remove the buffer. The solution was replaced with 20mM L-histidine acetate buffer, pH 6.0, 120mM sucrose, 0.2g/L polysorbate 20, to obtain ADC-6a (3.2mg/ml, 2ml).
- Dissolve DC-7 (0.9 mg, 0.8 mmol) in 0.09 ml of DMA, add it to the above solution system, mix well, and react with a rotating turntable at room temperature for 2 hours. After the reaction is completed, use a NAP-5 gel column (Cytiva) to remove the buffer. The solution was replaced with 20mM L-histidine acetate buffer, pH 6.0, 120mM sucrose. Sugar, 0.2g/L polysorbate 20, obtained ADC-7a (3.1mg/ml, 2ml).
- Dissolve DC-14 (0.63 mg, 0.8 mmol) in 0.063 ml of DMA, add it to the above solution system, mix well, and react with a rotating turntable at room temperature for 2 hours. After the reaction is completed, use a NAP-5 gel column (Cytiva) to remove the buffer. The solution was replaced with 20mM L-histidine acetate buffer, pH 6.0, 120mM sucrose, 0.2g/L polysorbate 20, to obtain ADC-14a (2.9mg/ml, 2ml).
- Dissolve DC-15 (0.62 mg, 0.8 mmol) in 0.062 ml of DMA, add it to the above solution system, mix well, and react with a rotating turntable at room temperature for 2 hours. After the reaction is completed, use a NAP-5 gel column (Cytiva) to remove the buffer. The solution was replaced with 20mM L-histidine acetate buffer, pH 6.0, 120mM sucrose, 0.2g/L polysorbate 20, to obtain ADC-15a (3.2mg/ml, 2ml).
- Human esophageal cancer cells OE33 and human breast adenocarcinoma cells SK-BR-3 were cultured in RPMI1640 (Cellmax) containing 10% fetal bovine serum (Cellmax). Dilute the tumor cells in the exponential growth phase to 1 ⁇ 10 5 cells/mL with culture medium, add 100 ⁇ L per well to a 96-well cell culture plate, and place them back in a 37°C, 5% CO 2 incubator for overnight culture. The next day, use culture medium to dilute the small molecule compounds to 10000nM, 2000nM, 400nM, 80nM, 16nM, 3.2nM, 0.64nM, 0.13nM, and add the diluted compounds to the 96-well cell culture plate at 2 ⁇ L per well.
- IC50 value “++++” means IC50 ⁇ 10nM;
- Human esophageal cancer cell OE33, lung cancer cell NCI-H1975 and breast cancer cell MDA-MB-231 were used as activity tests, respectively, containing 10% Culture in RPMI1640 (Cellmax), RPMI1640 (Cellmax) and DMEM (Cellmax) culture medium of fetal bovine serum (Cellmax) to the exponential growth phase. After trypsin digestion, centrifuge and discard the supernatant, and dilute with culture medium to 3 ⁇ respectively. 10 4 cells/mL, 0.5 ⁇ 10 4 cells/mL and 1.5 ⁇ 10 4 cells/mL were added to the 96-well cell culture plate at 100 ⁇ L per well, and placed back in a 37°C, 5% CO 2 incubator for overnight cultivation. .
- IC50 value "++++” means IC50 ⁇ 10nM;"+++” means IC50 is between 10nM-100nM; “++” means IC50 is between 100-500nM; "+” means IC50 >500 ⁇ M.
- the DXD structural formula of the positive control compound is:
- the example compounds provided by the present invention all have good inhibitory effects on the growth of cancer cells, such as esophageal cancer cells and breast adenocarcinoma cells 3. Most of the compounds, such as compounds 2, 3, 7, 8, 9, and 13, have a good inhibitory effect on esophageal cancer cells.
- the IC50 values of cell growth inhibition are all lower than 10nM, indicating significant anti-cancer activity.
- the compounds of the present invention are used to construct antibody-drug conjugates, and the resulting conjugates have significant inhibitory activity against esophageal cancer cells, lung cancer cells, and breast cancer cells.
- Exemplary conjugates ADC-3a, ADC- Both 6a and ADC-7a had significant inhibitory activity on the above cells, and the inhibitory activity of ADC-7a was even lower than 10 nM.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一系结构新颖的依沙替康衍生物、其药学上可接受的盐、立体异构体或前药,及其在抗肿瘤领域的应用,所述依沙替康衍生物具有式(I)所示结构。
Description
本发明涉及生物医药领域,具体涉及依沙替康衍生物及其应用。
依沙替康(Exatecan)是一种全合成的天然产物喜树碱的衍生物,对拓扑异构酶Top1具有极强的抑制活性,能促进肿瘤细胞凋亡,具有广谱的抗肿瘤活性。依沙替康由于其毒副作用大限制了其本身在抗肿瘤药物领域的应用,以其羟基乙酰胺衍生物(Dxd)为毒素和曲妥珠(trastuzumab,Herceptin)形成的抗体偶联药物DS-8201a(antibody-drugconjugate,ADC)对Her2表达的肿瘤具有非常好的治疗效果。DS-8201a是一款性能优良的ADC抗肿瘤药物。除Herceptin外,针对其它抗原如B7-H3、Trop2等的ADC药物也正在被广泛研究。
本发明在保持依沙替康的药效骨架的基础上对依沙替康进行羟胺和肼的衍生,形成一系列具有偶联位点的依沙替康衍生物,这些化合物兼备高抗肿瘤活性、低毒副作用、易溶于水的特点,作为抗肿瘤单药或抗体偶联药物具有潜在的应用价值。
发明内容
本发明提供了一系结构新颖的依沙替康衍生物、其药学上可接受的盐、立体异构体或前药,及其在抗肿瘤领域的应用。
本发明的一方面,提供式(I)化合物或其药学上可接受的盐、立体异构体或前药:
式中,
R选自-Z-R1,其中,Z为单键或C=O;
R1选自-(CH2)nNRaRb、-CH2ORa、-NORa、-(CH2)nONRaRb或-R3;n选自0、1、2或3;
Ra、Rb各自独立地选自氢、羟基、氨基、C1-C6烷基、C1-C6烷氨基、氨基C1-C6烷基或C1-C6烷氧基;
R3选自3至6元环烷基或含N、O、或S杂原子的3至6元杂环烷基,R3任选地进一步地被Rc取代;
Rc选自氢、羟基、氨基、C1-C6烷基、C1-C6烷氨基或C1-C6烷氧基;
条件是,-Z-R1不为-NH2、-CH2OH、-CH2NH2或-CH2OCH2NH2。
在一实施方案中,R1不为-CH2ONH2或羟基氧杂环丁烷基。
在一实施方案中,R1选自-NRaRb、-CH2NRaRb、-CH2ORa、-NORa、-(CH2)nONRaRb或-R3。
优选地,R1选自-NRaRb、-C(O)NRaRb、-CH2NRaRb、-CH2ONRaRb或-R3。
在一实施方案中,Ra、Rb各自独立地选自氢、羟基、氨基、C1-C6烷基、C1-C6烷氨基或C1-C6烷氧基。
优选地,Ra、Rb各自独立地选自氢、羟基、氨基、甲基、甲氨基或甲氧基。
在一实施方案中,R3选自含N、O、或S杂原子的3至6元杂环烷基,R3任选地进一步地被Rc取代;所述Rc选自氢、羟基、氨基、C1-C6烷基、C1-C6烷氨基或C1-C6烷氧基。
在一实施方案中,R1选自-NHNH2、-N(CH3)NH2、-N(CH3)NHCH3、-C(O)NHNH2、-C(O)N(CH3)NH2、-CH2NHOH、-CH2NHOCH3、-CH2ONH2、-CH2ONHCH3、-CH2NCH3NH2、-CH2N(CH3)NHCH3、-CH2N(CH3)OH、-CH2NHOCH2CH3、羟基氧杂环丁烷基氨基氧杂环丁烷基
在一实施方案中,R1选自-NHNH2、-N(CH3)NH2、-N(CH3)NHCH3、-C(O)NHNH2、-C(O)N(CH3)NH2、-
CH2NHOH、-CH2NHOCH3、-CH2ONHCH3、-CH2NCH3NH2、-CH2N(CH3)NHCH3、-CH2N(CH3)OH、-CH2NHOCH2CH3、氨基氧杂环丁烷基
在一实施方案中,所述式(I)化合物为式(Ia)化合物:
式中,R1定义同式(I)化合物。
优选地,R1为-NHNH2或-N(CH3)NH2。
在一实施方案中,所述式(I)化合物为式(Ib)化合物:
式中,R2选自-NHOH、-ONH2、-NHO(C1-C3烷基)、-ONH(C1-C3烷基)、-N(C1-C3烷氨基)、-N(C1-C3烷基)NH(C1-C3烷基)、-N(C1-C3烷基)OH或-NHO(C1-C3烷基)。
优选地,R2选自-NHOH、-NHOCH3、ONH2、-ONHCH3、-NCH3NH2、-N(CH3)NHCH3、-N(CH3)OH或-NHOCH2CH3。
在一实施方案中,R2选自-NHOH、-NHO(C1-C3烷基)、-ONH(C1-C3烷基)、-N(C1-C3烷氨基)、-N(C1-C3烷基)NH(C1-C3烷基)、-N(C1-C3烷基)OH或-NHO(C1-C3烷基)。
优选地,R2选自-NHOH、-NHOCH3、-ONHCH3、-NCH3NH2、-N(CH3)NHCH3、-N(CH3)OH或-NHOCH2CH3。
在一实施方案中,所述式(I)化合物为式(Ic)化合物:
式中,Ra、Rb定义同式(I)化合物;条件是,Ra、Rb不同时为H。
优选地,Ra、Rb各自独立地选自氢、氨基、C1-C3烷基、C1-C3烷氨基。
优选地,-NRaRb选自-NHNH2、-N(CH3)NH2或-N(CH3)NHCH3。
在一实施方案中,所述式(I)化合物为式(Id)化合物:
式中,X为CH2、NH、O或S。
优选地,X为CH2或O;更优选地,X为O。
在一实施方案中,Rc选自氢、羟基、氨基、C1-C6烷基、C1-C6烷氨基或C1-C6烷氧基。
优选地,Rc选自羟基或氨基,更优选为氨基。
在一实施方案中,所述式(I)化合物选自以下化合物:
值得注意的是,R1为-CH2ONH2时,其与化合物8(R1为-CH2ONHCH3)对OE33细胞生长抑制的IC50值虽然均低于10nM,但化合物8的IC50值仍显著低于R1为-CH2ONH2时得到的依沙替康衍生物化合物。
本发明的另一方面,提供上述任一项所述化合物的制备方法,其选自以下反应路线:
反应路线1:
将依沙替康和N,N'-羰基二咪唑反应,再和肼或取代的肼反应得到相应的N-氨基脲依沙替康衍生物。
例如,
反应路线2:
将取代的肼和草酰氯反应,再和依沙替康反应,得到相应的草酰胺肼依沙替康衍生物。
例如,
反应路线3:
依沙替康和溴乙酸反应得到溴乙酰基依沙替康,溴乙酰基依沙替康和胺类化合物进行缩合得到相应的酰胺依沙替康衍生物。
例如,
反应路线4:
依沙替康和羧酸类化合物直接反应得到相应的酰胺依沙替康衍生物。
例如,
式中,R、L定义同式(I)化合物。
本发明的再一方面,提供一种式(II)所示的药物-连接子化合物或其药学上可接受的盐、立体异构体或前药:
式中,R定义同式(I)化合物。
在一实施方案中,L为-L1-Q-L2;R与L1部分相连。
其中,L1选自其中,所示位置表示与R基团相连,所示位置表示与Q基团相连。
在一实施方案中,L2选自
在一实施方案中,Q选自Val-Cit、Val-Ala、Ala-Ala-Asn、Gly-Gly-Phe-Gly、Gly-Lys、Gly-Gly-lys、(CH2)m1O(CH2)m2、(CH2)m3,其中,m1和m2各自独立地选自1-4的整数。
优选地,m1为2。
优选地,m2为2。
优选地,m3为6。
在一实施方案中,Q选自Val-Cit、Gly-Gly-Phe-Gly、(CH2)2O(CH2)2、或(CH2)6;
优选地,L1为
优选地,L2为
本发明的再一方面,提供一种式(III)所示的药物-抗体偶联化合物或其药学上可接受的盐:
式中,R定义同式(I)或化合物,L定义同式(II)或化合物。
Ab为肿瘤相关抗原抗体,n选自1-8的整数。
优选地,所述肿瘤相关抗原选自Her2、Trop2、5T4、ROR1或B7-H3。
优选地,Ab为帕妥珠单抗(Pertuzumab)。
在一实施方案中,所述式(III)药物-抗体偶联化合物选自以下化合物:
优选地,所述式(II)药物-抗体偶联化合物选自以下化合物:
本发明的再一方面,提供一种药物组合物,其包括上述化合物、药物-连接子化合物或其药学上可接受的盐、立体异构体、前药或抗体药物偶联物。
所述药物组合物进一步还包括药学上可接受的辅料。
本发明的再一方面,提供一种上述化合物、药物-连接子化合物或其药学上可接受的盐、立体异构体、前药或抗体药物偶联物、药物组合物在制备用于治疗癌症的药物中的应用。
优选地,所述癌症包括胃癌、食管癌、乳腺癌和肺腺癌。
本发明的另一方面,提供一种治疗癌症的方法,其包括向有需要的患者施用上述化合物或其药学上可接受的盐、立体异构体、前药、抗体药物偶联物或药物组合物的步骤。
在一实施方案中,上述化合物或其药学上可接受的盐、立体异构体、前药、抗体药物偶联物或药物组合物的施用量为治疗有效量。
I.定义
在本发明中,除非另有说明,否则本文中使用的科学和技术名词具有本领域技术人员所通常理解的含义。并且,本文中所用的相关术语和实验室操作步骤均为相应领域内广泛使用的术语和常规步骤。同时,为了更好地理解本发明,下面提供相关术语的定义和解释。
如本文使用的和除非另作说明,术语“包含”,“包括”,“具有”,“含有”,包括其语法上的等同形式,通常应当理解为开放式且非限制性的,例如,不排除其他未列举的要素或步骤。
本发明化合物可以是不对称的,例如,具有一个或多个立体异构体。除非另有说明,所有立体异构体都包括,如对映异构体和非对映异构体。所述的立体异构体包括几何异构(如顺式、反式结构)和光学异构(如对映异构体),以单体、消旋体、外消旋混合物及其药学上可接受的盐组成的治疗物。本发明的含有不对称碳原子的化合物可以以光学活性纯的形式或外消旋形式被分离出来。光学活性纯的形式可以从外消旋混合物拆分,或通过使用手性原料或手性试剂合成。外消旋体、非对映异构体、对映异构体都包括在本发明的范围之内。
本发明化合物还包括互变异构体形式。互变异构体形式来源于一个单键与相邻的双键交换并一起伴随一个质子的迁移。
如本文所用,“药学上可接受的盐”是指相应的胺类化合物和无机酸或有机酸形成的盐,或相应的羧酸类化合物和碱金属或碱土金属形成的盐或和有机胺形成的盐。其中,无机酸包括但不限于盐酸,氢溴酸,氢碘酸,硫酸,磷酸等;有机酸包括但不限于乙酸,丙酸,丁酸,苯甲酸,甲磺酸,苯磺酸,对甲苯磺酸,草酸,丁二酸,乳酸,柠檬酸,琥珀酸,葡萄糖酸,马来酸,延胡索酸,酒石酸等;碱金属或碱土金属盐包括但不限于钠、钾、钙、镁盐等;有机胺盐包括但不限于氨、甲胺、乙胺、丙胺、异丙胺、二甲胺、二乙胺、三甲胺、三乙胺、叔丁胺、乙二胺、乙醇胺、二乙醇胺、三乙醇胺、吗啉、哌啶、哌嗪、氨基酸等组成的盐。
如本文所用,“前体”是指化合物以适当的给药方式进入人体后,前体化合物在病人体内进行代谢或简单的化学变化而转变成本发明通式1中所包含的化合物以及相应的盐的形式。化合物的前体包括但不限于各种羧酸酯、碳酸酯、磷酸酯、硫酸酯、磺酸酯、氨基酸酯、葡萄糖酸酯以及各种酰胺、缩醛、半缩醛、碳酸酰胺酯等形式。
本文中的数字范围,是指给定范围中的各个整数。例如,“C1-C6”是指该基团可具有1个碳原子、2个碳原子、3个碳原子、4个碳原子、5个碳原子或6个碳原子;“C3-C6”是指该基团可具有3个碳原子、4个碳原子、5个碳原子或6个碳原子。
当任何变量(例如Rn)在化合物的组成或结构中出现一次以上时,其在每一种情况下的定义都是独立的。因此,例如,如果一个基团被1-5个R所取代,则所述基团可以任选地至多被5个R所取代,并且每种情况下的R都有独立的选项。此外,取代基和/或其变体的组合只有在这样的组合会产生稳定的化合物的情况下才是被允许的。
术语“烷基”指饱和脂肪族烃基团,其为包含1至20个碳原子的直链或支链基团,优选含有1至8个碳原子的烷基,更优选1至6个碳原子的烷基,最优选1至3个碳原子的烷基。非限制性实例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2_二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基、正庚基、2-甲基己基、3-甲基己基、4-甲基己基、5-甲基己基、2,3-二甲基戊基、2,4-二甲基戊基、2,2-二甲基戊基、3,3-二甲基戊基、2-乙基戊基、3-乙基戊基、正辛基、2,3-二甲基己基、2,4-二甲基己基、2,5-二甲基己基、2,2-二甲基己基、3,3-二甲基己基、4,4-二甲基己基、2-乙基己基、3-乙基己基、4-乙基己基、2-甲基-2-乙基戊基、2-甲基-3-乙基戊基、正壬基、2-甲基-2-乙基己基、2-甲基-3-乙基己基、2,2-二乙基戊基、正癸基、2,2-二乙基己基、2,2-二乙基己基,及其各种支链异构体等。更优选的是含有1至6个碳原子的低级烷基,非限制性实施例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基等。烷基可以是取代的或非取代的,当被取代时,取代基可以在任何可使用的连接点上被取代,所述取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氧代基、羧基或羧酸酯基,本发明优选甲基、乙基、异丙基、叔丁基、卤代烷基、氘代烷基、烷氧基取代的烷基和羟基取代的烷基。
术语“杂环基”指饱和或部分不饱和单环或多环环状烃取代基,其包含3至20个环原子,其中一个或多个环原子为选自氮、氧或S(O)m(其中m是整数0至2)的杂原子,但不包括-O-O-、-O-S-或-S-S-的环部分,其余环原子
为碳。优选包含3至12个环原子,其中1-4个是杂原子;更优选包含3至8个环原子;最优选包含3至8个环原子;进一步优选包含1-3氮原子的3-8元杂环基,任选地,被1-2个氧原子、硫原子、氧代基取代,包括含氮单环杂环基、含氮螺杂环基或含氮稠杂环基。
术语“芳基”指具有共轭的π电子体系的6至14元全碳单环或稠合多环(也就是共享毗邻碳原子对的环)基团,优选为6至12元,例如苯基和萘基。
芳基可以是取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、琉基、氢基,硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、羧基或羧酸酯基。
术语“烷氧基”指-O-(烷基)和-O-(非取代的环烷基),其中烷基的定义如上所述。烷氧基的非限制性实例包括:甲氧基、乙氧基、丙氧基、丁氧基、环丙氧基、环丁氧基、环戊氧基、环己氧基。烷氧基可以是任选取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、疏基、氢基、硝基、氯基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、羧基或羧酸酯基。
本发明所述的氢原子均可被其同位素氘所取代。
“取代的”指基团中的一个或多个氢原子,优选为最多5个,更优选为1-3个氢原子彼此独立地被相应数目的取代基取代。不言而喻,取代基仅处在它们的可能的化学位置,本领域技术人员能够在不付出过多努力的情况下确定(通过实验或理论)可能或不可能的取代。例如,具有游离氢的氨基或羟基与具有不饱和(如烯属)键的碳原子结合时可能是不稳定的。
是指化学键连接处。
药物或药物组合物
如本文所用,“药学上可接受的盐”是指相应的胺类化合物和无机酸或有机酸形成的盐,或相应的羧酸类化合物和碱金属或碱土金属形成的盐或和有机胺形成的盐。其中,无机酸包括但不限于盐酸,氢溴酸,氢碘酸,硫酸,磷酸等;有机酸包括但不限于乙酸,丙酸,丁酸,苯甲酸,甲磺酸,苯磺酸,对甲苯磺酸,草酸,丁二酸,乳酸,柠檬酸,琥珀酸,葡萄糖酸,马来酸,延胡索酸,酒石酸等;碱金属或碱土金属盐包括但不限于钠、钾、钙、镁盐等;有机胺盐包括但不限于氨、甲胺、乙胺、丙胺、异丙胺、二甲胺、二乙胺、三甲胺、三乙胺、叔丁胺、乙二胺、乙醇胺、二乙醇胺、三乙醇胺、吗啉、哌啶、哌嗪、氨基酸等组成的盐。
如本文所用,“前体”是指化合物以适当的给药方式进入人体后,前体化合物在病人体内进行代谢或简单的化学变化而转变成本发明通式1中所包含的化合物以及相应的盐的形式。化合物的前体包括但不限于各种羧酸酯、碳酸酯、磷酸酯、硫酸酯、磺酸酯、氨基酸酯、葡萄糖酸酯以及各种酰胺、缩醛、半缩醛、碳酸酰胺酯等形式。
本发明的药物或药物组合物可以经口地、局部地、肠胃外地或粘膜地(例如,含服地、通过吸入或直肠地)以包含常规的非-毒性药学可接受的载体的剂量单位配制剂施用。通常希望使用口服途径。所述活性试剂可以经口地以胶囊、片剂等形式(参见Remington:The Science and Practice of Pharmacy,20th Edition)施用。
对于以片剂或胶囊形式的口服给药,活性药物组分可以与非-毒性的、药学可接受的辅料如粘结剂(例如,预胶化的玉米淀粉、聚乙烯吡咯烷酮或羟丙基甲基纤维素);填料(例如,乳糖、蔗糖、葡萄糖、甘露糖醇、山梨糖醇和其它还原性和非-还原性糖类、微晶纤维素、硫酸钙或磷酸氢钙);润滑剂(例如,硬脂酸镁、滑石粉或硅土、硬脂酸、硬脂基富马酸酯钠、甘油二十二烷酸酯、硬脂酸钙等);崩解剂(例如,马铃薯淀粉或羟乙酸淀粉钠);或润湿剂(例如,月桂基硫酸钠)、着色剂和调味剂、明胶、甜味剂、天然和合成的胶(如阿拉伯胶、黄蓍胶或藻朊酸盐)、缓冲盐、羧甲纤维素、聚乙二醇、蜡、等。对于以液体形式的口服给药,所述药物组分可以与非-毒性、药学可接受的惰性载体(例如,乙醇、甘油、水)、防沉降剂(例如,山梨糖醇糖浆、纤维素衍生物或氢化的可食用脂肪)、乳化剂(例如,卵磷脂或阿拉伯胶)、非-水性载体(例如,扁桃油、油酯类、乙醇或经分馏的植物油)、保藏剂(例如,p-羟基苯甲酸甲酯或p-羟基苯甲酸丙酯或山梨酸)等组合。还可以加入稳定剂如抗氧化剂(BHA、BHT、桔酸丙酯、抗坏血酸钠、柠檬酸)以稳定所述剂型。
包含作为活性化合物的片剂可以通过本领域熟知的方法包衣。包含作为活性化合物的式I化合物的本发明的所述组合物还可以引入小珠、微球或微胶囊,例如由聚乙醇酸/乳酸(PGLA)构建的。用于口服给药的液体的制剂可以采取例如溶液,糖浆剂,乳液或混悬液的形式或者它们可以呈现为在使用前用水或其它适宜的辅料重构的干产品。用于口服给药的制剂可以适宜地配制以使活性化合物受控或延迟地释放。
术语“治疗”包括抑制、缓解、预防或消除与所治疗的疾病、病症或失调相关的一种或多种症状或副作用。
术语“抑制”的使用是相对于对照的。本领域技术人员将容易地确定用于每个实验的适当对照。例如,将用化合物处理的受试者或细胞中的降低了的反应与未用化合物处理的受试者或细胞中的反应进行比较。
术语“药物组合物”意指包含本发明所述化合物或其药学上可接受的盐,以及依施用方式和剂型的性质而定的至少一种选自以下药学上可接受的成分的组合物,包括但不限于:载体、稀释剂、佐剂、赋形剂、防腐剂、填充剂、崩解剂、润湿剂、乳化剂、悬浮剂、甜味剂、矫味剂、香味剂、抗菌剂、抗真菌剂、润滑剂、分散剂、温敏材料、温度调节剂、黏附剂、稳定剂、助悬剂等。
术语“有效量”或“治疗有效量”是指无毒的但能达到预期效果的药物或药剂的足够用量。在本发明的实施方式中,在根据本发明对患者进行治疗时,给定药物的量取决于诸多因素,如具体的给药方案、疾病或病症类型及其严重性、需要治疗的受治疗者或宿主的独特性(例如体重),但是,根据特定的周围情况,包括例如已采用的具体药物、给药途径、治疗的病症、以及治疗的受治疗者或宿主,施用剂量可由本领域已知的方法常规决定。通常,就成人治疗使用的剂量而言,施用剂量典型地在0.02-5000mg/天,例如约1-1500mg/天的范围。该所需剂量可以方便地被表现为一剂、或同时给药的(或在短时间内)或在适当的间隔的分剂量,例如每天二、三、四剂或更多分剂。本领域技术人员可以理解的是,尽管给出了上述剂量范围,但具体的有效量可根据患者的情况并结合医师诊断而适当调节。
术语“抗体药物偶联物(antibody-drug conjugate,ADC)”抗体药物偶联物是通过一个化学链接将具有生物活性的小分子药物连接到单抗上,单抗作为载体将小分子药物靶向运输到目标细胞中。
如本文所用,术语“减少”、“抑制”、“减轻”或“减小”的使用是相对于对照的。本领域技术人员将容易地确定用于每个实验的适当对照。例如,将用化合物处理的受试者或细胞中的降低了的反应与未用化合物处理的受试者或细胞中的反应进行比较。
如无特别说明,本发明具体实施方式中使用的原料、设备均为已知产品,通过购买市售产品获得。
缩写
CDI:N,N′-羰基二咪唑;EA:乙酸乙酯;DCM:二氯甲烷;HATU:2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯;DIPEA:N,N-二异丙基乙胺;NMP:N-甲基吡咯烷酮;HOBt:1-羟基苯并三唑;
Val:缬氨酸,其结构式为Cit:瓜氨酸,其结构式为Gly:甘氨酸,其结构式为Phe:苯丙氨酸,其结构式为Fmoc:苏氨酸磷酸苄酯,其结构式为Val-Cit:Gly-Gly-Phe-Gly:
Val-Ala、Ala-Ala-Asn、Gly-Lys、Gly-Gly-lys等连接链的连接方式可采用本领公知的氨基酸缩合方法。
-Pab-:-ha-:mc-:ba-:bp-:
II.具体实施例
本实施例中制备ADC使用但不限于帕妥珠单抗(PERTUZUMAB),其重链氨基酸序列如下(SEQ ID NO:1):
轻链氨基酸序列如下(SEQ ID NO:2):
实施例1:依沙替康-N-氨基脲(1)
在1ml的DMF中,加入依沙替康甲磺酸盐(30mg,56.44μmol)和三乙胺(11.42mg,112.88μmol),搅拌均匀后,加入CDI(9.15mg,56.44μmol),在氩气保护下,室温反应1h,依次加入三乙胺(80mg)和盐酸肼(19.33mg,0.28mmol),室温搅拌反应10h,加入50ml的EA,饱和食盐水洗涤,萃取、分相,无水硫酸钠干燥,硅胶柱层析分离纯化,得到化合物1(25mg,产率90%);1H NMR(500MHz,DMSO-d6)δ7.77(d,J=10.9Hz,1H),7.54(s,1H),7.30(s,1H),6.52(m,1H),5.41(m,2H),5.39-5.33(m,1H),5.22(m,J=7.0Hz,2H),3.15(m,J=13.6,6.9Hz,2H),3.06(s,2H),2.38(s,3H),2.24-2.11(m,2H),1.86(m,J=21.4,7.0Hz,2H),0.87(t,J=7.3Hz,3H);LCMS:(M+1)+493.98(计算值:493.18)。
实施例2:依沙替康-N-甲基-N-氨基脲(2)
在1ml的DMF中,加入依沙替康甲磺酸盐(30mg,56.44μmol)和三乙胺(11.42mg,112.88μmol),搅拌均匀后,加入CDI(9.15mg,56.44μmol),在氩气保护下,室温反应1h,依次加入三乙胺(80mg)和1-Boc-2-甲基肼(45.05mg,0.3mmol),室温搅拌反应10h,加入50ml的EA,饱和食盐水洗涤,萃取、分相,无水硫酸钠干燥,硅胶柱层析分离纯化得到化合物Boc-产物,将Boc-产物溶于1ml DCM中,加入0.5ml 4M盐酸的乙酸乙酯溶液,室温搅拌反应30min,得到化合物2(22mg,产率80%);1H NMR(500MHz,DMSO-d6)δ7.81(d,J=10.9Hz,1H),7.32(s,1H),6.54(s,1H),5.43(m,J=18Hz,3H),5.29(d,J=4.1Hz,2H),3.29(s,3H)3.17(t,J=6.4Hz,2H),2.41(d,J=1.7Hz,3H),2.20(m,J=13.0,6.9Hz,2H),1.86(m,J=20.7,13.7,6.8Hz,2H),0.87(t,J=7.3Hz,3H);LCMS:(M+1)+508.02(计算值:507.19)。
实施例3:依沙替康-N',N-二甲氨基脲(3)
在1ml的DMF中,加入依沙替康甲磺酸盐(30mg,56.44μmol)和三乙胺(11.42mg,112.88μmol),搅拌均匀后,加入CDI(9.15mg,56.44μmol),在氩气保护下,室温反应1h,依次加入TEA(80mg)和N’N-二甲基肼盐酸盐(45.05mg,0.33mmol),室温下搅拌反应10h,加入50ml的EA,饱和食盐水洗涤,分相,无水硫酸钠干燥,硅胶柱层析分离纯化,得到化合物3(18mg,产率62%;1H NMR(500MHz,DMSO-d6)δ7.76(d,J=10.9Hz,1H),7.48(d,J=9.2Hz,1H),7.30(s,1H),6.51(s,1H),5.41(s,2H),5.31(dd,J=17.0,8.5Hz,2H),5.16(s,1H),4.64(q,J=5.7Hz,2H),3.09(dt,J=16.8,7.8Hz,2H),3.01(s,3H),2.38(s,3H),2.18(t,J=7.2Hz,3H),1.86(dq,J=19.3,7.1Hz,2H),1.47(s,1H),0.86(d,
J=8.2Hz,3H);LCMS:(M+1)+522.02(计算值:521.21)。
实施例4:依沙替康-N’-氨基草酰二胺(4)
在30ml的DCM中,加入Boc-肼(5.93g,44.90mmol),TEA(6.2g,61.21mmol),搅拌溶清后,0℃下滴加草酰氯甲酯(5g,40.81mmol)的DCM溶液(50ml),室温下搅拌反应1h,饱和食盐水洗涤(20ml*3),无水硫酸钠干燥,浓缩得到化合物4-a N’-Boc-N-草酰肼单甲酯(7.1g,产率79%);LCMS:(M+1)+219.01(计算值:218.21)。
将化合物4-a(7.1g,32.56mmol)溶于70ml的乙醇中,然后滴加1M的LiOH水溶液32.53ml,室温搅拌过夜,然后滴加0.5M HCl水溶液调节反应液pH至5,减压去除水分和乙醇,浓缩液中加入5ml的甲醇和15ml DCM,搅拌1h,过滤,滤液浓缩得到化合物4-b N’-Boc-N-草酰肼(6g,产率89%),LCMS:(M+1)+205.2(计算值:204.18)。
在2ml的DMF中,依次加入依沙替康甲磺酸盐(200mg,0.37mmol),二异丙基乙胺(6.15mg,0.047mmol),N’-Boc-N-草酰肼(164mg,0.8mmol),HATU(286mg,0.75mmol),室温搅拌反应4小时,减压除去DMF,浓缩液加入到20ml的DCM,硅胶柱层析纯化得到化合物4-c依沙替康-N’-Boc-氨基草酰二胺(180mg,产率77%),LCMS:(M+1)+622.1(计算值:621.22)。
将依沙替康-N’-Boc-氨基草酰二胺(180mg,0.29mmol)溶于2ml DCM中,加入1ml 4M盐酸的乙酸乙酯溶液,室温搅拌反应30min,浓缩得到化合物4即依沙替康-N’-氨基草酰二胺(162mg,100%);1H NMR(500MHz,DMSO-d6)δ9.54(d,J=8.9Hz,1H),7.77(m,J=11.3,4.1Hz,1H),7.30(s,1H),6.52(s,1H),5.53(m,J=8.3,5.0Hz,1H),5.39(s,2H),5.12(d,J=4.0Hz,2H),3.23(s,1H),2.38(s,3H),2.28-2.15(m,2H),1.85(m,J=25.0,7.2Hz,2H),0.86(t,J=7.4Hz,3H);LCMS:(M+1)+522.00(计算值:521.17)。
实施例5:依沙替康N’-氨基-N-甲基草酰二胺(5)
在20ml的DCM中,加入1-甲基-2-Boc肼(2.4g,26mmol),TEA(1.65g,16.3mmol),搅拌溶清后,0℃下滴加草酰氯甲酯(2g,16.3mmol)的DCM溶液(20ml),室温下搅拌反应1h,萃取,饱和食盐水洗涤(10ml*3),无水硫酸钠干燥,浓缩后得到中间体化合物5-a1-甲基-2-Boc-草酰肼单甲酯(3.5g,产率92%),LCMS:(M+1)+233.10(计算值:232.24)。
将化合物5-a(3.5g,15mmol)溶于40ml的乙醇中,滴加1M的LiOH水溶液16.37ml,室温搅拌过夜,然后滴加0.5M HCl水溶液调节反应液pH至5,减压除水分和乙醇,浓缩液中加入2ml的甲醇和8ml DCM,搅拌1h,
过滤,滤液浓缩得到中间体化合物5-b 1-甲基-2-Boc-草酰肼(3.21g,产率90%),LCMS:(M+1)+219.01(计算值:218.21)。
在2ml的DMF中,依次加入依沙替康甲磺酸盐(100mg,0.19mmol),DIPEA(48.58mg,0.37mmol),化合物5-b(82mg,0.37mol),HATU(118mg,0.32mmol),室温搅拌反应4小时,减压除去DMF,硅胶纸层析分离纯化得到中间体化合物5-c依沙替康N’-Boc氨基-N-甲基草酰二胺(91mg,收率75%),LCMS:(M+1)+636.14(计算值:635.65)。
将化合物5-c(91mg,0.14mmol)溶于2ml DCM中,加入1ml 4M盐酸的乙酸乙酯溶液,室温搅拌反应30min,浓缩得到化合物5即依沙替康N’-氨基-N-甲基草酰二胺(85mg,收率100%);1H NMR(500MHz,DMSO-d6)δ8.87(d,J=8.7Hz,1H),7.79(d,J=10.9Hz,1H),7.31(s,1H),5.59-5.62(m,J=18Hz,1H),5.46-5.32(m,J=84Hz,4H),3.16-3.10(m,2H),2.95(s,2H),2.40(s,3H),2.17(ddq,J=28.2,14.0,5.5,4.9Hz,2H),1.86(dp,J=20.9,7.0Hz,2H),0.86(t,J=7.4Hz,3H);LCMS:(M+1)+536.03(计算值:535.53)。
实施例6:2-羟氨基乙酰依沙替康(6)
在1ml的DMF中,加入依沙替康甲磺酸盐(100mg,0.19mmol),TEA(25mg,0.24mmol),搅拌溶清后加入溴乙酸(40mg,0.28mmol),HATU(85mg,0.22mmol),室温搅拌反应1h,减压去除DMF,硅胶柱层析分离纯化得到中间体6-a依沙替康-N-溴乙酰胺(90mg,产率86%),LCMS:(M+1)+557.1(计算值:556.39)。
在10ml的瓶子里,加入1ml的DMF,然后依次加入盐酸羟胺(113mg,1.63mmol),TEA(164mg,1.62mmol),化合物6-a(90mg,0.16mmol),室温搅拌反应1h,减压除去DMF,硅胶柱层析分离纯化得到化合物6即2-羟氨基乙酰依沙替康(90mg,产率86%);1H NMR(500MHz,DMSO-d6)δ10.86-10.38(m,1H),8.96(d,J=8.7Hz,1H),7.82(t,J=11.9Hz,1H),7.32(s,1H),6.55(s,1H),5.77-5.54(m,1H),5.41(d,J=10.6Hz,2H),5.37-5.16(m,2H),3.86(m,J=11.7,8.0Hz,2H),3.31-3.02(m,3H),2.40(d,J=14.0Hz,3H),2.29-2.07(m,2H),1.86(m,J=21.6,7.2Hz,2H),0.86(t,J=7.3Hz,3H);LCMS:(M+1)+509.3(计算值:508.18)。
实施例7:2-甲氧氨基乙酰依沙替康(7)
在10ml的瓶子里,加入1ml的DMF,然后依次加入盐酸甲氧基胺(126mg,1.5mmol),TEA(182mg,1.79mmol),化合物6-a(100mg,0.18mmol),室温搅拌反应1h,减压去除DMF,硅胶柱层析分离纯化得到化合物7即2-甲氧氨基乙酰依沙替康(80mg,产率86%);1H NMR(500MHz,DMSO-d6)δ8.50-8.46(m,1H),7.80(d,J=10.8Hz,1H),7.30(d,J=1.9Hz,1H),6.83(td,J=6.2,1.8Hz,1H),6.52(d,J=1.9Hz,1H),5.61-5.55(m,1H),5.42(s,2H),5.22(s,2H),4.01-3.87(m,1H),3.42(d,J=6.1Hz,3H),3.17(t,J=6.4Hz,2H),2.40(s,3H),2.22-2.11(m,2H),1.86(dp,J=21.1,7.1Hz,2H),0.90-0.83(m,3H);LCMS:(M+1)+523.20(计算值:522.19)。
实施例8:2-甲氨氧基乙酰依沙替康(8)
在40ml的水和40ml THF的混合液中,加入N-甲基羟胺盐酸盐(10g,119.7mmol),搅拌溶清,加入碳酸钾(8.27g,60mmol),缓慢滴加Boc酸酐(28.75g,131.7mmol)的50ml THF溶液,滴毕,室温搅拌过夜,减压去除THF,用DCM(100ml*3)萃取,无水硫酸钠干燥,浓缩得到化合物8-a N-Boc-N-甲基羟胺(15g,收率88%),LCMS:(M+1)+148.01(计算值:147.17)。
将化合物8-a(15g,101.9mmol)溶解在100ml异丙醇中,加入溴乙酸甲酯(18.58g,121.4mmol)和DIPEA(15.7g,121.7mmol)氩气保护下升温至85℃反应3h,浓缩反应液,100ml EA溶解,饱和食盐水洗涤(30ml*3),无水硫酸钠干燥,浓缩得到化合物8-b N-Boc-N-甲基胺氧基乙酸甲酯(18g,产率81.8%),LCMS:(M+1)+220.21(计算值:219.24)。
在180ml甲醇中溶解化合物8-b(18g,82mmol),加入82.2ml的1M氢氧化锂水溶液,室温搅拌反应,反应完,浓缩反应液,去除甲醇,加入0.5mmol/L的盐酸水溶液调节酸性至pH=3左右,EA萃取,分相,干燥,过滤,浓缩得到化合物8-c N-Boc-N-甲基胺氧基乙酸(13.1g,产率77.3%),LCMS:(M+1)+206.01(计算值:205.21)。
在2ml的DMF中,依次加入依沙替康甲磺酸盐(100mg,0.19mmol),DIPEA(48.58mg,0.37mmol)化合物8-c(77.3mg,0.37mmol),HATU(118mg,0.31mmol),室温搅拌反应6小时,减压除去DMF,硅胶柱层析分离纯化得到化合物8-d N-Boc-N-甲氨氧基乙酰依沙替康(68mg,产率75%),LCMS:(M+1)+623.30(计算值:622.65)。
将化合物8-d(68mg,0.109mmol)溶于2ml DCM中,加入1ml 4M盐酸的乙酸乙酯溶液,室温搅拌反应30min,浓缩得到化合物8即2-甲氨氧基乙酰依沙替康盐酸盐(61mg,产率100%);1H NMR(500MHz,DMSO-d6)δ8.93(d,J=8.5Hz,1H),7.79(d,J=10.5Hz,1H),7.30(s,1H),5.60(dt,J=8.3,4.1Hz,1H),5.42(s,2H),5.29(s,2H),4.73-4.64(m,2H),3.18(s,2H),2.85(s,3H),2.39(s,3H),2.25(dt,J=8.8,4.6Hz,1H),2.19-2.10(m,1H),1.85(dp,J=21.4,7.2Hz,2H),0.86(t,J=7.3Hz,3H);LCMS:(M+1)+523.10(计算值:522.19)。
实施例9:2-N-甲基-N-氨基乙酰依沙替康(9)
在10ml的瓶子里,加入1ml的DMF,然后依次加入1-甲基-2-Boc肼(36.41mg,0.25mmol)TEA(54.6mg,0.54mmol),6-a(100mg,0.18mmol),室温搅拌反应1h,减压去除DMF,硅胶柱层析分离纯化得到化合物9-a2-N-甲基-N-Boc氨基乙酰依沙替康(72mg,产率63%);LCMS:(M+1)+622.30(计算值:621.21)。
将化合物9-a(72mg,0.115mmol)溶于2ml DCM中,加入1ml 4M盐酸的乙酸乙酯溶液,室温搅拌反应30min,得到9即2-N-甲基-N-氨基乙酰依沙替康(64mg,产率100%);1H NMR(500MHz,DMSO-d6)δ8.53(d,J=8.9Hz,1H),8.33(s,1H),7.79(d,J=10.9Hz,1H),7.32-7.27(m,1H),6.53(d,J=1.6Hz,1H),5.60(dt,J=9.3,5.1Hz,1H),5.41(s,2H),5.29-5.15(m,2H),3.42-3.40(m,2H),3.38-3.37(m,2H),3.37(s,3H),3.19(d,J=5.6Hz,1H),2.39(s,
3H),2.15(q,J=6.0Hz,2H),1.85(dp,J=21.7,7.0Hz,2H),0.86(t,J=7.3Hz,3H);LCMS:(M+H)+522.1(计算值:521.18)。
实施例10:2-N-甲基-N-甲氨基乙酰依沙替康(10)
在10ml的瓶子里,加入1ml的DMF,然后依次加入1,2-二甲基-二盐酸肼(71.72mg,0.54mmol),TEA(91mg,0.89mmol),6-a(100mg,0.18mmol),室温搅拌反应1h,反应完,减压去除DMF,硅胶柱层析分离纯化得到化合物10即2-N-甲基-N-甲氨基乙酰依沙替康(85mg,产率88%);1H NMR(500MHz,DMSO-d6)δ10.05(s,1H),8.85(d,J=9.1Hz,1H),7.81(m J=19.4,10.9Hz,1H),7.32(d,J=11.1Hz,1H),6.54(s,1H),5.66-5.51(m,1H),5.49-5.38(m,2H),5.35-5.17(m,2H),3.73-3.55(m,1H),3.19(m,J=19.8,15.3,9.5Hz,3H),2.73(s,3H),2.41(d,J=9.0Hz,3H),2.19(m,J=31.1,13.1,5.4Hz,2H),1.86(m,J=21.7,14.7,7.5Hz,2H),0.87(t,J=7.3Hz,3H);LCMS:(M+1)+536.20(计算值:535.22)。
实施例11:2-N-甲基羟氨基乙酰依沙替康(11)
在10ml的瓶子里,加入1ml的DMF,然后依次加入氮甲基羟胺盐酸盐(30mg,0.36mmol),TEA(58mg,0.57mmol),化合物6-a(100mg,0.18mmol),室温搅拌反应1h,减压去除DMF,硅胶柱层析分离纯化得到化合物11即2-N-甲基羟氨基乙酰依沙替康(70mg,产率75%);1H NMR(500MHz,DMSO-d6)δ8.44(d,J=12.4Hz,1H),7.79(t,J=10.7Hz,1H),7.30(d,J=4.9Hz,1H),6.63-6.41(m,1H),5.59(m,J=8.6,5.0Hz,1H),5.41(d,J=3.0Hz,2H),5.32-5.12(m,2H),3.17(m,J=5.3Hz,2H),2.73(d,J=6.7Hz,3H),2.39(d,J=6.0Hz,3H),2.24-2.08(m,2H),1.85(m,J=21.3,7.1Hz,2H),0.86(t,J=7.3Hz,3H);LCMS:(M+H)+523.20(计算值:522.19)。
实施例12:2-乙氧氨基乙酰依沙替康(12)
在10ml的瓶子里,加入1ml的DMF,然后依次加入乙氧基羟胺盐酸盐(126mg,1.29mmol),TEA(182mg,1.8mmol),化合物6-a(100mg,0.18mmol),室温搅拌反应1h,减压去除DMF,硅胶柱层析分离纯化得到化合物12即2-乙氧氨基乙酰依沙替康(81mg,产率83%);1H NMR(500MHz,DMSO-d6)δ7.79(m,J=11.0,5.7Hz,1H),7.31(s,1H),5.63(m,J=9.2,5.4Hz,1H),5.42(s,2H),5.31-5.16(m,2H),3.72-3.68(m,2H),3.45-3.42(m,2H),3.18(m,J=17.3,9.0Hz,2H),2.40(d,J=6.4Hz,3H),2.27-2.10(m,2H),1.86(m,J=21.7,14.6,7.3Hz,2H),1.24(m,J=7.1Hz,1H),1.00(m,J=6.9Hz,2H),0.87(m,J=6.8Hz,3H);LCMS:(M+1)+537.10(计算值:536.21)。
实施例13:3-氨基氧杂环丁烷-3-乙酰依沙替康(13)
在10ml的水和10ml EtOH的混合液中,加入3-氨基氧杂环丁烷-3-羧酸(0.5g,4.27mmol),搅拌溶清,加入碳酸氢钠(0.72g,8.54mmol),缓慢滴加Boc酸酐(0.98g,4.48mmol)的5ml EtOH溶液,滴毕,室温搅拌2h,减压去除乙醇,滴加盐酸,调节PH至4左右,用DCM(100ml*3)萃取产品,无水硫酸钠干燥,浓缩得到化合物15-a,N-Boc-3-氨基氧杂环丁烷-3-羧酸(0.8g,收率86%),LCMS:(M+1)+118.01(计算值:117.10)。
在1ml的DMF中,依次加入依沙替康甲磺酸盐(20mg,0.038mmol),DIPEA(9.7mg,0.074mmol)化合物13-a(16.5mg,0.075mmol),HATU(23.6mg,0.062mmol),室温搅拌反应6小时,减压除去DMF,硅胶柱层析分离纯化得到化合物15-b,N-Boc-3-氨基氧杂环丁烷-3-乙酰依沙替康(15mg,产率65%),LCMS:(M+1)+635.20(计算值:634.66)。
将化合物13-b(15mg,0.023mmol)溶于2ml DCM中,加入1ml 4M盐酸的乙酸乙酯溶液,室温搅拌反应30min,浓缩得到化合物13即3-氨基氧杂环丁烷-3-乙酰依沙替康(61mg,产率100%);1H NMR(500MHz,DMSO-d6)δ8.55(m,2H),8.10(d,J=8.8Hz,1H),7.76(m,1H),7.30(d,J=7.1Hz,1H),5.60-5.49(m,1H),5.42(m,2H),5.00-4.95(m,1H),4.88(d,J=6.2Hz,1H),4.57(d,J=6.3Hz,1H),4.51(d,J=6.2Hz,1H),3.62(m,1H),3.46(m,1H),3.23(m,1H),3.16-3.11(m,2H),2.38(m,3H),2.25-2.13(m,2H),1.92-1.78(m,2H),0.87(m,3H);LCMS:(M+1)+535.31(计算值:534.54)。
实施例14:mc-Val-Cit-pab-甲酰-2-N-甲基-N-氨基乙酰依沙替康(DC-1)
在0.3ml的NMP中,依次加入化合物9(14.14mg,0.027mmol),DIPEA(17.52mg,0.135mmol),mc-Val-Cit-pab-PNP(20mg,0.027mmol),HOBt(7.33mg,0.054mmol),室温反应1h,将反应液注射入25g C18预柱(先用乙腈平衡,然后用水平衡,水相含0.1%TFA),然后通过中压反相C18色谱法(梯度:10%至55%乙腈在水中,时间40min)洗脱,冻干,得到化合物DC-1即mc-Val-Cit-pab-甲酰-2-N-甲基-N-氨基乙酰依沙替康(15.2mg,产率50%)黄色固体;LCMS:(M+1)+1121.09(计算值:1120.21)。
实施例15:mc-Val-Cit-pab-甲酰-2-N-甲基-N-甲氨基乙酰依沙替康(DC-2)
在0.3ml的NMP中,依次加入化合物10(14.52mg,0.027mmol),DIPEA(10.51mg,0.081mmol),mc-Val-Cit-pab-PNP(20mg,0.027mmol),HOBt(7.33mg,0.054mmol),室温反应1h,将反应液注射入25g C18预柱(先用乙腈平衡,然后用水平衡,水相含0.1%TFA),然后通过中压反相C18色谱法(梯度:10%至55%乙腈在水中,
时间40min)洗脱,冻干,得到化合物DC-2即mc-Val-Cit-pab-甲酰-2-N-甲基-N-甲氨基乙酰依沙替康(12.2mg,40%)黄色固体;LCMS:(M+1)+1135.02(计算值:1134.23)。
实施例16:mc-Val-Cit-pab-甲酰-依沙替康-N-氨基脲(DC-3)
在0.3ml的NMP中,依次加入化合物1(13.38mg,0.027mmol),DIPEA(10.51mg,0.081mmol),mc-Val-Cit-pab-PNP(20mg,0.027mmol),HOBt(3.66mg,0.027mmol),室温反应1h,将反应液注射入25g C18预柱(先用乙腈平衡,然后用水平衡,水相含0.1%TFA),然后通过中压反相C18色谱法(梯度:10%至55%乙腈在水中,时间40min)洗脱,冻干,得到化合物DC-3即mc-Val-Cit-pab-甲酰-依沙替康-N-氨基脲(13mg,45%)黄色固体;LCMS:(M+1)+1093.03(计算值:1092.15)。
实施例17:mc-Val-Cit-pab-甲酰-依沙替康-N-甲基-N-氨基脲(DC-4)
在0.3ml的NMP中,依次加入化合物2(13.7mg,0.027mmol),DIPEA(10.51mg,0.081mmol),mc-Val-Cit-pab-PNP(20mg,0.027mmol),HOBt(3.66mg,0.027mmol),室温反应1h,将反应液注射入25g C18预柱(先用乙腈平衡,然后用水平衡,水相含0.1%TFA),然后通过中压反相C18色谱法(梯度:15%至60%乙腈在水中,时间40min)洗脱,冻干,得到化合物DC-4即mc-Val-Cit-pab-甲酰-依沙替康-N-甲基-N-氨基脲(9mg,30%)黄色固体;LCMS:(M+1)+1107.11(计算值:1106.18)。
实施例18:mc-Val-Cit-pab-甲酰-依沙替康-N’,N-二甲氨基脲(DC-5)
在0.3ml的NMP中,依次加入化合物3(14.11mg,0.027mmol),DIPEA(10.51mg,0.081mmol),mc-Val-Cit-pab-PNP(20mg,0.027mmol),HOBt(3.66mg,0.027mmol),室温反应1h,将反应液注射入25g C18预柱(先用乙腈平衡,然后用水平衡,水相含0.1%TFA),然后通过中压反相C18色谱法(梯度:15%至60%乙腈在水中,时间40min)洗脱,冻干,得到化合物DC-5即mc-Val-Cit-pab-甲酰-依沙替康-N’,N-二甲氨基脲(12.1mg,40%)黄色固体;LCMS:(M+1)+1121.02(计算值:1120.21)。
实施例19:mc-Val-Cit-pab-甲酰-2-氨氧基乙酰依沙替康(DC-6)
在2ml的DMF中,依次加入依沙替康甲磺酸盐(100mg,0.19mmol),DIPEA(48.58mg,0.37mmol),叔丁氧羰酰氨氧基乙酸(45mg,0.23mmol),HATU(118mg,0.31mmol),室温搅拌反应4小时,减压除去DMF,硅胶柱层析纯化得到中间体化合物2-Boc-氨氧基乙酰依沙替康(95mg,产率83%);1H NMR(500MHz,DMSO-d6)δ10.40(s,1H),8.73(d,J=8.6Hz,1H),7.75(d,J=10.8Hz,1H),7.28(d,J=2.1Hz,1H),6.52(d,J=1.5Hz,1H),5.62(dt,J=8.8,4.4Hz,1H),5.40(d,J=3.3Hz,2H),5.23(d,J=17.9Hz,1H),5.19-5.11(m,1H),4.32(d,J=15.8Hz,1H),4.23(d,J=15.9Hz,1H),3.23-3.15(m,2H),2.37(d,J=6.5Hz,3H),2.24(dq,J=14.1,4.9Hz,1H),2.17(tt,J=8.3,5.1Hz,1H),1.84(ddp,J=21.4,14.3,7.2Hz,2H),1.15(s,9H),0.85(t,J=7.2Hz,3H);LCMS:(M+1)+609.30(计算值:608.18)。
将化合物2-Boc-氨氧基乙酰依沙替康(95mg,0.16mmol)溶于1ml DCM中,加入1ml 4M盐酸的乙酸乙酯溶液,室温搅拌反应30min,浓缩得到化合物14即2-氨氧基乙酰依沙替康(85mg,产率100%);1H NMR(500MHz,DMSO-d6)δ8.93(d,J=8.5Hz,1H),7.79(d,J=10.5Hz,1H),7.30(s,1H),5.60(dt,J=8.3,4.1Hz,1H),5.42(s,2H),5.29(s,2H),4.73-4.64(m,2H),3.18(s,2H),2.85(s,3H),2.39(s,3H),2.25(dt,J=8.8,4.6Hz,1H),2.19-2.10(m,1H),1.85(dp,J=21.4,7.2Hz,2H),0.86(t,J=7.3Hz,3H);LCMS:(M+1)+509.20(计算值:508.18)。
在0.7ml的NMP中,依次加入化合物14(32.17mg,0.063mmol),DIPEA(24.53mg,0.189mmol),mc-Val-Cit-pab-PNP(70mg,0.095mmol),HOBt(8.55mg,0.063mmol),室温反应1h,将反应液注射入25g C18预柱(先用乙腈平衡,然后用水平衡,水相含0.1%TFA),然后通过中压反相C18色谱法(梯度:10%至55%乙腈在水中,时间40min)洗脱,冻干,得到化合物DC-6即mc-Val-Cit-pab-甲酰-2-氨氧基乙酰依沙替康(31.5mg,31%)黄色固体;LCMS:(M+1)+1108.10(计算值:1107.16)。
实施例20:mc-Val-Cit-pab-甲酰-N-甲基氨氧乙酰依沙替康(DC-7)
在0.7ml的NMP中,依次加入化合物8(33.05mg,0.063mmol),DIPEA(24.53mg,0.189mmol),mc-Val-Cit-pab-PNP(70mg,0.095mmol),HOBt(8.55mg,0.063mmol),室温反应1h,将反应液注射入25g C18预柱(先用乙腈平衡,然后用水平衡,水相含0.1%TFA),然后通过中压反相C18色谱法(梯度:10%至55%乙腈在水中,时间40min)洗脱,冻干,得到化合物DC-7即mc-Val-Cit-pab-甲酰-2-甲氨氧基乙酰依沙替康(42mg,39%)黄色固体;LCMS:(M+1)+1122.05(计算值:1121.09)。
实施例21:mc-Val-Cit-pab-甲酰-依沙替康-N’-氨基草酰二胺(DC-8)
在0.3ml的NMP中,依次加入化合物4(14.14mg,0.027mmol),DIPEA(17.52mg,0.135mmol),mc-Val-Cit-pab-PNP(20mg,0.027mmol),HOBt(3.66mg,0.027mmol),室温反应1h,将反应液注射入25g C18预柱(先用乙腈平衡,然后用水平衡,水相含0.1%TFA),然后通过中压反相C18色谱法(梯度:10%至55%乙腈在水中,时间40min)洗脱,冻干,得到化合物DC-8即mc-Val-Cit-pab-甲酰-依沙替康-N’-氨基草酰二胺(13mg,45%)黄
色固体;LCMS:(M+1)+1121.02(计算值:1120.16)。
实施例22:mc-Val-Cit-pab-甲酰-依沙替康N’-氨基-N-甲基草酰二胺(DC-9)
在0.3ml的NMP中,依次加入化合物5(14.52mg,0.027mmol),DIPEA(17.52mg,0.135mmol),mc-Val-Cit-pab-PNP(20mg,0.027mmol),HOBt(3.66mg,0.027mmol),室温反应1h,将反应液注射入25g C18预柱(先用乙腈平衡,然后用水平衡,水相含0.1%TFA),然后通过中压反相C18色谱法(梯度:10%至55%乙腈在水中,时间40min)洗脱,冻干,得到化合物DC-9即mc-Val-Cit-pab-甲酰-依沙替康N’-氨基-N-甲基草酰二胺(13mg,45%)黄色固体;LCMS:(M+1)+1135.10(计算值:1134.19)。
实施例23:mc-Val-Cit-pab-甲酰-N-羟基氨乙酰依沙替康(DC-l0)
在0.3ml的NMP中,依次加入化合物6(13.79mg,0.027mmol),DIPEA(10.51mg,0.081mmol),mc-Val-Cit-pab-PNP(20mg,0.027mmol),HOBt(3.66mg,0.027mmol),室温反应1h,将反应液注射入25g C18预柱(先用乙腈平衡,然后用水平衡,水相含0.1%TFA),然后通过中压反相C18色谱法(梯度:5%至50%乙腈在水中,时间40min)洗脱,冻干,得到化合物DC-10即mc-Val-Cit-pab-甲酰-N-羟基氨乙酰依沙替康(13mg,45%)黄色固体;LCMS:(M+1)+1108.03(计算值:1107.16)。
实施例24:mc-Val-Cit-pab-甲酰-N-甲氧氨乙酰依沙替康(DC-11)
在0.3ml的NMP中,依次加入化合物7(14.17mg,0.027mmol),DIPEA(10.51mg,0.081mmol),mc-Val-Cit-pab-PNP(20mg,0.027mmol),HOBt(3.66mg,0.027mmol),室温反应1h,将反应液注射入25g C18预柱(先用乙腈平衡,然后用水平衡,水相含0.1%TFA),然后通过中压反相C18色谱法(梯度:15%至50%乙腈在水中,时间40min)洗脱,冻干,得到化合物DC-11即mc-Val-Cit-pab-甲酰-N-甲氧氨乙酰依沙替康(13mg,45%)黄色固体;LCMS:(M+1)+1122.06(计算值:1121.19)。
实施例25:mc-Val-Cit-pab-甲酰-N-乙氧基氨乙酰依沙替康(DC-12)
在0.3ml的NMP中,依次加入化合物12(14.17mg,0.027mmol),DIPEA(10.51mg,0.081mmol),mc-Val-Cit-pab-PNP(20mg,0.027mmol),HOBt(3.66mg,0.027mmol),室温反应1h,将反应液注射入25g C18预柱(先用乙腈平衡,然后用水平衡,水相含0.1%TFA),然后通过中压反相C18色谱法(梯度:15%至50%乙腈在水中,时间40min)洗脱,冻干,得到化合物DC-12即mc-Val-Cit-pab-甲酰-N-乙氧基氨乙酰依沙替康(13mg,45%)黄色固体;LCMS:(M+1)+1136.02(计算值:1135.20)。
实施例26:mc-Gly-Gly-Phe-Gly-甲氧-N-甲基氨乙酰依沙替康(DC-13)
取Fmoc-Gly-Gly-Phe-OH(10g,19.9mmol),加入200mL DCM,HATU(11.43g,29.85mmol),DIPEA(5.13g.39.8mmol)和Gly-Gly-OtBu(4.11g,21.89mmol),室温反应15h,加入200mL DCM稀释,饱和碳酸氢钠溶液洗涤,无水硫酸钠干燥,硅胶柱层析纯化得白色固体DC-13-a,Fmoc-Gly-Gly-Phe-Gly-Gly-OtBu(10.7g,79%);LCMS:(M+1)+672.5(计算值:671.75)。
取DC-13-a(10.7g,15.9mmol),加入110mL DCM和50mL TFA,室温反应15h反浓缩应液,加入100ml EA,过滤,滤饼在40℃烘箱干燥,得类白色固体DC-13-b,Fmoc-Gly-Gly-Phe-Gly-Gly(8.8g,90%);LCMS:(M+1)+616.10(计算值:615.23)。
取DC-13-b(3g,4.8mmol)溶于30mL DMF中,搅拌溶解,依次加入醋酸铜(1.46mmol,0.26g),醋酸(9.7mmol,0.58g),四乙酸铅(5.3mmol,2.38g),升温至60℃,反应20min,将反应液倒进冰水中,加入乙酸乙酯萃取,无水硫酸钠干燥后,浓缩拿到类白色固体产品DC-13-c,Fmoc-Gly-Gly-Phe-Gly-N-羟甲基醋酸酯(1.81g,59%);LCMS:(M+1)+630.10(计算值:629.25)。
取DC-13-c(0.05g,0.076mmol),加入5mL THF,再加入化合物11(0.04g,0.076mmol)和PPTS(3.8mg,0.015mmol),氩气保护下,60℃回流反应16h,硅胶柱层析纯化得白色固体DC-13-d,Fmoc-Gly-Gly-Phe-Gly-甲氧-N-甲基氨乙酰依沙替康(43mg,50%);LCMS:(M+1)+1093.05(计算值:1092.15)。
将DC-13-d(43mg,0.039mmol)溶于0.5ml的DMF中,加入哌啶(33mg,0.39mmol),室温搅拌反应1h,浓缩反应液,得到黄棕色固体DC-13-e,Gly-Gly-Phe-Gly-甲氧-N-甲基氨乙酰依沙替康(34mg,100%);LCMS:(M+1)+871.02(计算值:869.91)。
将DC-13-e(34mg,0.039mmol)溶解于0.5ml无水DMF中,依次加入6-(马来酰亚胺基)己酸琥珀酰亚胺酯(12mg,0.039mmol),DIPEA(5mg,0.039mmol),室温反应30min,将反应液注射入25g C18预柱(先用乙腈平衡,然后用水平衡,水相含0.1%TFA),然后通过中压反相C18色谱法(梯度:15%至50%乙腈在水中,时间40min)洗脱,冻干,得到化合物DC-13即mc-Gly-Gly-Phe-Gly-甲氧-N-甲基氨乙酰依沙替康(12.4mg,30%)黄色固体;LCMS:(M+1)+1064.05(计算值:1063.11)。
实施例27:4-(马来酰亚胺己基氧)苯甲醛-氨氧乙酰依沙替康肟(DC-14)
在100ml单口瓶中,依次加入6-氨基-1-己醇(6.0g 51.20mmol),60ml 48%浓度HBr水溶液,90℃回流搅拌反应18h,在冰浴条件下使用碳酸氢钠固体将反应液pH调节至8-9之间,加入Boc酸酐(11.2g 51.20mmol),缓慢升至室温搅拌过夜,过滤反应液,滤液使用EtOAc萃取目标产物,有机相使用5%NaCl溶液洗涤三次后使用无水Na2SO4干燥,过滤干燥后的有机相,浓缩后得到类白色固体产品N-Boc-6-溴己胺(10.0g,产率71.4%);LCMS:(M+1)+281.12(计算值:280.21)。
在100ml单口瓶中加入50ml的乙腈,依次加入N-Boc-6-溴己胺(5.0g 17.84mmol),对羟基苯甲醛(2.2g17.84mmol),无水碳酸钾(6.2g 44.61mmol),60℃回流搅拌反应18h,过滤反应液,滤液中加入10.0g硅胶制砂,使用PE和EA进行柱层析,浓缩拿到类白色固体产品4-(N-Boc-己烷氧基)苯甲醛(5.0g,产率87.7%);LCMS:(M+1)+322.14(计算值:321.42)。
在100ml单口瓶中加入3ml 1,4-二氧六环,依次加入4-(N-Boc-己烷氧基)苯甲醛(1.0g 4.52mmol),3ml 4mol/L HCl/1,4-二氧六环溶液,常温条件下搅拌反应3h,在冰浴条件下使用饱和碳酸氢钠溶液调节反应液的pH至9,加入N-甲氧基羰基顺丁烯二酰亚胺(700.90mg 4.52mmol),在冰浴条件下搅拌反应2h,过滤固体,滤饼使用10ml纯化水洗涤,滤饼在35度条件下烘干后拿到类白色固体产品L-20(1.0g,产率73.5%);LCMS:(M+1)+302.23(计算值:301.34)。
在3ml的甲醇中,加入L-20(24.59mg,0.081mmol),吡啶(14.2mg,0.179mmol),无水硫酸钠(23.18mg,0.163mmol),最后加入化合物14(83mg,0.163mmol),室温搅拌反应1h,反应完,加入1g硅胶柱层析拿到产品DC-14,4-(马来酰亚胺己基氧)苯甲醛-氨氧乙酰依沙替康肟(36mg,产率56%);LCMS:(M+1)+792.11(计算值:791.30)。
实施例28:4-(马来酰亚胺乙基氧乙氧基)苯甲醛-氨氧乙酰依沙替康肟(DC-15)
在100ml单口瓶中,依次加入二甘醇胺(6.0g 57.07mmol),60ml 48%浓度HBr水溶液,90℃回流搅拌反应18h,在冰浴条件下使用碳酸氢钠固体将反应液pH调节至8-9之间,加入Boc酸酐(12.46g 57.07mmol),缓慢升至室温搅拌过夜,过滤反应液,用EtOAc萃取目标产物,有机相使用5%NaCl溶液洗涤三次后使用无水Na2SO4干燥,过滤干燥后的有机相,浓缩后得到类白色固体产品N-Boc-溴乙氧基乙胺(10.8g,产率70.6%);LCMS:(M+1)+269.02(计算值:268.15)。
在100ml单口瓶中加入50ml的乙腈,依次加入N-Boc-溴乙氧基乙胺(5.0g 18.65mmol),对羟基苯甲醛(2.28g18.65mmol),无水碳酸钾(6.44g 46.62mmol),60℃回流搅拌反应18h,过滤反应液,滤液中加入10.0g硅胶制砂,使用PE和EA进行柱层析,浓缩拿到类白色固体产品4-(N-Boc-氨乙氧基乙氧基)苯甲醛(5.3g,产率91.8%);LCMS:(M+1)+310.24(计算值:309.36)。
在100ml单口瓶中加入3ml 1,4-二氧六环,依次加入4-(N-Boc-氨乙氧基乙氧基)苯甲醛(0.6g 1.94mmol),3ml 4mol/L HCl/1,4-二氧六环溶液,常温条件下搅拌反应3h,在冰浴条件下使用饱和碳酸氢钠溶液调节反应液的pH至9,加入N-甲氧基羰基顺丁烯二酰亚胺(300.83mg 1.94mmol),在冰浴条件下搅拌反应2h,过滤固体,滤饼使用10ml纯化水洗涤,滤饼在35度条件下烘干后拿到类白色固体产品L-021(500mg,产率89%);LCMS:(M+1)+
290.13(计算值:289.29)。
在3ml的甲醇中,加入L-021(23.61mg,0.082mmol),吡啶(14.2mg,0.179mmol),无水硫酸钠(23.18mg,0.163mmol),最后加入化合物14(83mg,0.163mmol),室温搅拌反应1h,反应完,加入1g硅胶柱层析拿到产品DC-15,4-(马来酰亚胺乙基氧乙氧基)苯甲醛-氨氧乙酰依沙替康肟(42mg,产率66%);LCMS:(M+1)+780.12(计算值:779.26)。
实施例29:HS627-丁二酰亚胺-N-己酰-Val-Cit-pab-甲酰-依沙替康-N-氨基脲(ADC-3a)
取HS627抗体(20.0mg/mL,10mg,0.066mmol),用1M Na2HPO4溶液调pH至7.2,然后再加入0.1M乙二胺四乙酸二钠的溶液(25μL),加入配置好的TCEP·HCl(三(2-羧乙基)膦盐酸盐)溶液(10mM,0.04ml),室温25℃旋转转盘反应90min。
将DC-3(0.9mg,0.8mmol)溶于0.09ml的DMA中,加入到上述溶液体系中,混匀,室温旋转转盘反应2h,反应完毕后用NAP-5凝胶柱(Cytiva)将缓冲液置换为20mM L-组氨酸醋酸盐缓冲液,pH6.0,120mM蔗糖,0.2g/L聚山梨酯20,得到ADC-3a(1.8mg/ml,3ml)。
UV-HPLC计算平均值:n=7.40
实施例30:HS627-丁二酰亚胺-N-己酰-Val-Cit-pab-甲酰-2-氨氧基乙酰依沙替康(ADC-6a)
取HS627抗体(20.0mg/mL,10mg,0.066mmol),用1M Na2HPO4溶液调pH至7.2,然后再加入0.1M乙二胺四乙酸二钠的溶液(25μL),加入配置好的TCEP·HCl(三(2-羧乙基)膦盐酸盐)溶液(10mM,0.04ml),室温25℃旋转转盘反应90min。
将DC-6(0.9mg,0.8mmol)溶于0.09ml的DMA中,加入到上述溶液体系中,混匀,室温旋转转盘反应2h,反应完毕后用NAP-5凝胶柱(Cytiva)将缓冲液置换为20mM L-组氨酸醋酸盐缓冲液,pH6.0,120mM蔗糖,0.2g/L聚山梨酯20,得到ADC-6a(3.2mg/ml,2ml)。
UV-HPLC计算平均值:n=7.70
实施例31:HS627-丁二酰亚胺-N-己酰-Val-Cit-pab-甲酰-N-甲基氨氧乙酰依沙替康(ADC-7a)
取HS627抗体(20.0mg/mL,10mg,0.066mmol),用1M Na2HPO4溶液调pH至7.2,然后再加入0.1M乙二胺四乙酸二钠的溶液(25μL),加入配置好的TCEP·HCl(三(2-羧乙基)膦盐酸盐)溶液(10mM,0.04ml),室温25℃旋转转盘反应90min。
将DC-7(0.9mg,0.8mmol)溶于0.09ml的DMA中,加入到上述溶液体系中,混匀,室温旋转转盘反应2h,反应完毕后用NAP-5凝胶柱(Cytiva)将缓冲液置换为20mM L-组氨酸醋酸盐缓冲液,pH6.0,120mM蔗
糖,0.2g/L聚山梨酯20,得到ADC-7a(3.1mg/ml,2ml)。
UV-HPLC计算平均值:n=7.30
实施例32:HS627-丁二酰亚胺-4-(N-己基氧)苯甲醛肟氧乙酰依沙替康(ADC-14a)
取HS627抗体(20.0mg/mL,10mg,0.066mmol),用1M Na2HPO4溶液调pH至7.2,然后再加入0.1M乙二胺四乙酸二钠的溶液(25μL),加入配置好的TCEP·HCl(三(2-羧乙基)膦盐酸盐)溶液(10mM,0.04ml),室温25℃旋转转盘反应90min。
将DC-14(0.63mg,0.8mmol)溶于0.063ml的DMA中,加入到上述溶液体系中,混匀,室温旋转转盘反应2h,反应完毕后用NAP-5凝胶柱(Cytiva)将缓冲液置换为20mM L-组氨酸醋酸盐缓冲液,pH6.0,120mM蔗糖,0.2g/L聚山梨酯20,得到ADC-14a(2.9mg/ml,2ml)。
UV-HPLC计算平均值:n=4.3。
实施例33:HS627-丁二酰亚胺-4-(N-乙氧基乙氧基)苯甲醛肟氧乙酰依沙替康(ADC-15a)
取HS627抗体(20.0mg/mL,10mg,0.066mmol),用1M Na2HPO4溶液调pH至7.2,然后再加入0.1M乙二胺四乙酸二钠的溶液(25μL),加入配置好的TCEP·HCl(三(2-羧乙基)膦盐酸盐)溶液(10mM,0.04ml),室温25℃旋转转盘反应90min。
将DC-15(0.62mg,0.8mmol)溶于0.062ml的DMA中,加入到上述溶液体系中,混匀,室温旋转转盘反应2h,反应完毕后用NAP-5凝胶柱(Cytiva)将缓冲液置换为20mM L-组氨酸醋酸盐缓冲液,pH6.0,120mM蔗糖,0.2g/L聚山梨酯20,得到ADC-15a(3.2mg/ml,2ml)。
UV-HPLC计算平均值:n=7.6。
效果例1:抑制肿瘤细胞生长活性
化合物(小分子毒素)体外抑制活性测试方法
将人食管癌细胞OE33、人乳腺腺癌细胞SK-BR-3分别在含有10%胎牛血清(Cellmax)的RPMI1640(Cellmax)中培养。将处于指数增长期的肿瘤细胞用培养基稀释至1×105cells/mL,以每孔100μL加入到96孔细胞培养板中,放回37℃,5%CO2的培养箱中过夜培养。第二天,使用培养基将小分子分别化合物稀释至10000nM、2000nM、400nM、80nM、16nM、3.2nM、0.64nM、0.13nM,并以每孔2μL将稀释后的化合物加入到96孔细胞培养板中,每个浓度设置3个复孔,未添加化合物的阴性对照和空白对照组每孔加入2μL的稀释液。加样完成后,放回37℃,5%CO2的培养箱中继续孵育72h。孵育完成后,取出细胞培养板,用移液器将培养板中的培养基吸弃,每孔加入100μL含有10%CCK-8的培养基,37℃孵育3h。孵育完成后,取出培养板,避光,置于酶标板中,选择630nm为参比波长,450nm为测定波长测定吸光度。根据吸光值,使用GraphPad中四参数回归计算IC50值(表1-3)。以DNA拓扑异构酶I抑制剂Dxd为阳性对照药物。对于IC50值,其中“++++”表示IC50<10nM;“+++”表示IC50介于10nM-100nM之间;“++”表示IC50介于100-500nM之间;“+”表示IC50>500μM。
ADC体外抑制活性测试方法
将作为活性检测的人食管癌细胞OE33、肺癌细胞NCI-H1975和乳腺癌细胞MDA-MB-231细胞分别在含有10%
胎牛血清(Cellmax)的RPMI1640(Cellmax)、RPMI1640(Cellmax)和DMEM(Cellmax)培养基中培养至指数增长期,胰酶消化后,离心弃上清,用培养基稀释至分别稀释至3×104cells/mL、0.5×104cells/mL和1.5×104cells/mL,以每孔100μL加入到96孔细胞培养板中,放回37℃,5%CO2的培养箱中过夜培养。第二天,使用培养基将待测ADC稀释至2000nM、400nM、80nM、16nM、3.2nM、0.64nM、0.128nM、0.026nM,并以每孔100μL将稀释后的ADC加入到96孔细胞培养板中,每个浓度设置3个复孔,未添加ADC的阴性对照和空白对照组每孔加入100μL的培养基。加样完成后,放回37℃,5%CO2的培养箱中继续孵育6天。孵育完成后,取出细胞培养板,用移液器将培养板中的培养基吸弃,每孔加入100μL含有10%CCK-8的培养基,37℃孵育3h。孵育完成后,取出培养板,避光,置于酶标板中,选择630nm为参比波长,450nm为测定波长测定吸光度。根据吸光值,使用GraphPad中四参数回归计算IC50(表1、3)。以ADC药物DS-8201a为阳性对照药物。对于IC50值,其中“++++”表示IC50<10nM;“+++”表示IC50介于10nM-100nM之间;“++”表示IC50介于100-500nM之间;“+”表示IC50>500μM。
阳性对照化合物DXD结构式为:
表1对OE33的抑制活性
表2对SK-BR-3的抑制活性
表3 ADC药物对NCI-H1975和MDA-MB-231的抑制活性
本发明提供的实施例化合物均对癌细胞例如食管癌细胞、乳腺腺癌细胞3的生长均具有较好的抑制作用,大部分化合物例如化合物2、3、7、8、9、13对食管癌细胞生长抑制的IC50值均低于10nM,具有显著的抗癌活性。
本发明实施例化合物用于构建抗体-药物偶联物,其得到的偶联物对食管癌细胞、肺癌细胞和乳腺癌细胞均具有显著的抑制活性,示例性偶联物ADC-3a、ADC-6a和ADC-7a对上述细胞均具有明显的抑制活性,ADC-7a的抑制活性甚至均低于10nM。
Claims (11)
- 式(I)化合物或其药学上可接受的盐、立体异构体或前药:
式中,R选自-Z-R1,其中,Z为单键或C=O;R1选自-(CH2)nNRaRb、-CH2ORa、-NORa、-(CH2)nONRaRb或-R3;n选自0、1、2或3;Ra、Rb各自独立地选自氢、羟基、氨基、C1-C6烷基、C1-C6烷氨基、氨基C1-C6烷基或C1-C6烷氧基;R3选自3至6元环烷基或含N、O、或S杂原子的3至6元杂环烷基,R3任选地进一步地被Rc取代;Rc选自氢、羟基、氨基、C1-C6烷基、C1-C6烷氨基或C1-C6烷氧基;条件是,-Z-R1不为-NH2、-CH2OH、-CH2NH2或-CH2OCH2NH2。 - 根据权利要求1所述的化合物或其药学上可接受的盐、立体异构体或前药,其特征在于,R1选自-NRaRb、-CH2NRaRb、-CH2ORa、-NORa、-(CH2)nONRaRb或-R3;优选地,R1选自-NRaRb、-C(O)NRaRb、-CH2NRaRb或-CH2ONRaRb或-R3;优选地,Ra、Rb各自独立地选自氢、羟基、氨基、C1-C6烷基、C1-C6烷氨基或C1-C6烷氧基;优选地,Ra、Rb各自独立地选自氢、羟基、氨基、甲基、甲氨基或甲氧基;R3选自含N、O、或S杂原子的3至6元杂环烷基,R3任选地进一步地被Rc取代;Rc选自氢、羟基、氨基、C1-C6烷基、C1-C6烷氨基或C1-C6烷氧基。
- 根据权利要求2所述的化合物或其药学上可接受的盐、立体异构体或前药,其中,R1选自-NHNH2、-N(CH3)NH2、-N(CH3)NHCH3、-C(O)NHNH2、-C(O)N(CH3)NH2、-CH2NHOH、-CH2NHOCH3、-CH2ONH2、-CH2ONHCH3、-CH2NCH3NH2、-CH2N(CH3)NHCH3、-CH2N(CH3)OH、-CH2NHOCH2CH3、羟基氧杂环丁烷基、氨基氧杂环丁烷基。
- 根据权利要求1-3任一项所述的化合物或其药学上可接受的盐、立体异构体或前药,所述式(I)化合物为式(Ia)、(Ib)、(Ic)或(Id)所示化合物:
式(Ia)中,R1定义同式(I)化合物;优选地,R1为-NHNH2或-N(CH3)NH2;
式(Ib)中,R2选自-NHOH、-ONH2、-NHO(C1-C3烷基)、-ONH(C1-C3烷基)、-N(C1-C3烷氨基)、-N(C1-C3烷 基)NH(C1-C3烷基)、-N(C1-C3烷基)OH或-NHO(C1-C3烷基);优选地,R2选自-NHOH、-NHOCH3、-ONH2、-ONHCH3、-NCH3NH2、-N(CH3)NHCH3、-N(CH3)OH或-NHOCH2CH3;
式(Ic)中,Ra、Rb定义同式(I)化合物;条件是,Ra、Rb不同时为H;优选地,Ra、Rb各自独立地选自氢、氨基、C1-C3烷基、C1-C3烷氨基;优选地,-NRaRb选自-NHNH2、-N(CH3)NH2或-N(CH3)NHCH3;
式(Id)中,X为CH2、NH、O或S;优选地,X为CH2或O;更优选地,X为O;Rc选自氢、羟基、氨基、C1-C6烷基、C1-C6烷氨基或C1-C6烷氧基;优选地,Rc选自羟基或氨基。 - 以下化合物或其药学上可接受的盐、立体异构体或前药:
- 权利要求1-5任一项所述化合物的制备方法,其选自以下反应路线:反应路线1:将依沙替康和N,N'-羰基二咪唑反应,再和肼或取代的肼反应得到相应的N-氨基脲依沙替康衍生物;反应路线2:将取代的肼和草酰氯反应,再和依沙替康反应,得到相应的草酰胺肼依沙替康衍生物;反应路线3:依沙替康和溴乙酸反应得到溴乙酰基依沙替康,溴乙酰基依沙替康和胺类化合物进行缩合得到相应的酰胺依沙替康衍生物;反应路线4:依沙替康和羧酸类化合物直接反应得到相应的酰胺依沙替康衍生物。
- 式(II)所示的药物-连接子化合物或其药学上可接受的盐、立体异构体或前药:
式中,R定义同式(I)化合物;L为-L1-Q-L2;R与L1部分相连;其中,L1选自其中,所示位置表示与R基团相连,所示位置表示与Q基团相连;L2选自Q选自Val-Cit、Val-Ala、Ala-Ala-Asn、Gly-Gly-Phe-Gly、Gly-Lys、Gly-Gly-lys、(CH2)m1O(CH2)m2或(CH2)m3,其中,m1和m2各自独立地选自1-4的整数;m1优选为2;m2优选为2;m3优选为6;优选地,Q选自Val-Cit、Gly-Gly-Phe-Gly、(CH2)2O(CH2)2、或(CH2)6;优选地,L1为优选地,L2为 - 式(III)所示的药物-抗体偶联化合物或其药学上可接受的盐:
式中,R定义同式(I)或化合物,L定义同式(II)或化合物;Ab为肿瘤相关抗原抗体,n选自1-8的整数;优选地,所述肿瘤相关抗原选自Her2、Trop2、5T4、ROR1或B7-H3;优选地,所述式(III)药物-抗体偶联化合物选自以下化合物:
优选地,所述式(III)药物-抗体偶联化合物选自以下化合物:
- 药物组合物,其特征在于,包括权利要求1-5任一项所述的化合物、权利要求7所述的药物-连接子化合物或其药学上可接受的盐、立体异构体、前药或权利要求8所述的抗体药物偶联物和药学上可接受的辅料。
- 权利要求1-5任一项所述的化合物、权利要求7所述的药物-连接子化合物或其药学上可接受的盐、立体异构体、前药或权利要求8所述的抗体药物偶联物或权利要求9所述的药物组合物在制备用于治疗癌症的药物中的应用;优选地,所述癌症包括胃癌、食管癌、乳腺癌和肺腺癌。
- 治疗癌症的方法,其包括向有需要的患者施用权利要求1-5任一项所述的化合物、权利要求7所述的药物-连接子化合物或其药学上可接受的盐、立体异构体、前药或权利要求8所述的抗体药物偶联物或权利要求9所述的药物组合物的步骤。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210920035.1 | 2022-07-29 | ||
CN202210920035 | 2022-07-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024022165A1 true WO2024022165A1 (zh) | 2024-02-01 |
Family
ID=88637923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/107930 WO2024022165A1 (zh) | 2022-07-29 | 2023-07-18 | 依沙替康衍生物及其应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117024438A (zh) |
WO (1) | WO2024022165A1 (zh) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105829346A (zh) * | 2014-01-31 | 2016-08-03 | 第三共株式会社 | 抗her2抗体-药物偶联物 |
WO2020063673A1 (zh) * | 2018-09-30 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | 抗b7h3抗体-依喜替康类似物偶联物及其医药用途 |
CN111065621A (zh) * | 2017-08-31 | 2020-04-24 | 第一三共株式会社 | 制备抗体-药物缀合物的新方法 |
CN113816969A (zh) * | 2021-04-30 | 2021-12-21 | 联宁(苏州)生物制药有限公司 | 依喜替康类化合物、其抗体药物偶联物及其应用 |
WO2022068878A1 (zh) * | 2020-09-30 | 2022-04-07 | 映恩生物制药(苏州)有限公司 | 一种抗肿瘤化合物及其制备方法和应用 |
WO2022236136A1 (en) * | 2021-05-07 | 2022-11-10 | ALX Oncology Inc. | Exatecan derivatives and antibody-drug conjugates thereof |
CN115557962A (zh) * | 2021-07-02 | 2023-01-03 | 石药集团巨石生物制药有限公司 | 新型喜树碱类化合物及其制备方法和应用 |
CN116063311A (zh) * | 2023-03-01 | 2023-05-05 | 普方生物制药(苏州)有限公司 | 一种依喜替康衍生物及其制备方法 |
WO2023138635A1 (zh) * | 2022-01-18 | 2023-07-27 | 甘李药业股份有限公司 | 一种依喜替康衍生物-抗体偶联物及其医药用途 |
WO2023163234A1 (ja) * | 2022-02-28 | 2023-08-31 | Ube株式会社 | 抗体・薬物コンジュゲート前駆体およびその合成中間体 |
WO2023163227A1 (ja) * | 2022-02-28 | 2023-08-31 | Ube株式会社 | 抗体-薬物コンジュゲート |
-
2023
- 2023-06-16 CN CN202310723322.8A patent/CN117024438A/zh active Pending
- 2023-07-18 WO PCT/CN2023/107930 patent/WO2024022165A1/zh unknown
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105829346A (zh) * | 2014-01-31 | 2016-08-03 | 第三共株式会社 | 抗her2抗体-药物偶联物 |
CN111065621A (zh) * | 2017-08-31 | 2020-04-24 | 第一三共株式会社 | 制备抗体-药物缀合物的新方法 |
WO2020063673A1 (zh) * | 2018-09-30 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | 抗b7h3抗体-依喜替康类似物偶联物及其医药用途 |
WO2022068878A1 (zh) * | 2020-09-30 | 2022-04-07 | 映恩生物制药(苏州)有限公司 | 一种抗肿瘤化合物及其制备方法和应用 |
CN113816969A (zh) * | 2021-04-30 | 2021-12-21 | 联宁(苏州)生物制药有限公司 | 依喜替康类化合物、其抗体药物偶联物及其应用 |
WO2022236136A1 (en) * | 2021-05-07 | 2022-11-10 | ALX Oncology Inc. | Exatecan derivatives and antibody-drug conjugates thereof |
CN115557962A (zh) * | 2021-07-02 | 2023-01-03 | 石药集团巨石生物制药有限公司 | 新型喜树碱类化合物及其制备方法和应用 |
WO2023138635A1 (zh) * | 2022-01-18 | 2023-07-27 | 甘李药业股份有限公司 | 一种依喜替康衍生物-抗体偶联物及其医药用途 |
WO2023163234A1 (ja) * | 2022-02-28 | 2023-08-31 | Ube株式会社 | 抗体・薬物コンジュゲート前駆体およびその合成中間体 |
WO2023163227A1 (ja) * | 2022-02-28 | 2023-08-31 | Ube株式会社 | 抗体-薬物コンジュゲート |
CN116063311A (zh) * | 2023-03-01 | 2023-05-05 | 普方生物制药(苏州)有限公司 | 一种依喜替康衍生物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN117024438A (zh) | 2023-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021078301A1 (zh) | 蛋白降解剂及其在疾病治疗中的应用 | |
RU2489423C2 (ru) | Водорастворимые аналоги сс-1065 и их конъюгаты | |
WO2021027911A1 (zh) | 新型螺环类K-Ras G12C抑制剂 | |
ES2375841T3 (es) | Nueva forma cristalina de un derivado de piridazino[4,5-b]indol. | |
WO2018157856A1 (zh) | 酰胺类衍生物抑制剂及其制备方法和应用 | |
CN109071423A (zh) | 吲哚胺-2,3-双加氧酶(ido)抑制剂 | |
JP2021512059A (ja) | ブルトン型チロシンキナーゼ(btk)阻害剤のe3リガーゼリガンドとのコンジュゲーションによるbtkの分解および使用方法 | |
CN110981870B (zh) | 基于pH和GSH双重响应的β-咔啉-环烯酮衍生物及其用途 | |
BRPI0619331A2 (pt) | método para fazer um composto para preparar um análogo de cbi cc-1065, método para preparar um análogo de cbi cc-1065 e composto | |
WO2011153814A1 (zh) | 吡咯取代的2-二氢吲哚酮衍生物、其制备方法及用途 | |
WO2009124468A1 (zh) | 具有高活性的四环蒽醌类抗生素的衍生物及其制备和应用 | |
WO2022063297A1 (zh) | 喹唑啉衍生物及其制备方法和用途 | |
JP2016532714A (ja) | アルファ−tea塩形態:疾患を処置するための組成物および使用 | |
CN110914253A (zh) | 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途 | |
CN113710276A (zh) | 苯二氮䓬衍生物作为rsv抑制剂 | |
CN111217815A (zh) | 含有喋啶酮骨架的化合物及其制备方法和应用 | |
JP5393482B2 (ja) | 抗癌活性を有するテトラサイクリン・アントラキノン系化合物 | |
CN117069793A (zh) | 双功能接头化合物、抗体药物偶联物及其制备方法和应用 | |
WO2024022167A1 (zh) | 喜树碱衍生物及其制备方法和应用 | |
WO2024051502A1 (zh) | 喜树碱-7-乙基胺衍生物及其制备方法和应用 | |
WO2013131465A1 (zh) | N-(4-(3-氟苄氧基)-3-氯苯基)-6-(5-((2-(甲基亚砜基)乙基氨基)甲基)-2-呋喃基)-喹唑啉-4-胺二甲苯磺酸盐的多晶型物及其制备方法和用途 | |
AU2005327442A1 (en) | Novel betulinic acid derivatives a-ring-condensed to a heterocyclic group | |
WO2024022165A1 (zh) | 依沙替康衍生物及其应用 | |
CN116712563A (zh) | N-卤代烷基取代的喜树碱衍生物的抗体偶联药物 | |
CN110467616B (zh) | 含杂芳基取代哒嗪酮结构的三唑并吡嗪类化合物的制备及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23845377 Country of ref document: EP Kind code of ref document: A1 |